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ABSTRACT 
 
 
  In the USA, 200,000 brain tumors are diagnosed each year with glioma 
representing 8.4% of the 200,000. The standard treatment for glioma consists of surgical 
resection, when possible, followed by radiation therapy (RT) and/or chemotherapy. 
Radiation therapy is one of the most effective treatments of brain tumors; however, the 
therapeutic ratio of RT is limited by damage to the normal tissue. We hypothesize that 
tumor growth has an adverse effect on the peritumoral tissue through the 
angiogenic/inflammatory environment it creates rendering it susceptible to further 
damage by RT which may be prevented by using anti-angiogenic/anti-inflammatory 
agents. We have developed a rat C6 glioma brain tumor model to study the combination 
of tumor presence and radiation treatment on the peritumoral region both at early and late 
time points. We have also used this model to test the effect of thalidomide on limiting 
radiation toxicity to the normal tissue while not interfering with radiation efficacy.  
 
  Intravital microscopy was used in combination with a cranial window brain 
tumor model to assess the effect of glioma presence on neighboring tissue with and 
without RT (40Gy total, 8Gy/day starting on day 5 post-implant/surgery) and when RT 
was administered in combination with thalidomide (100mg/kg/day). Permeability of the 
blood-brain barrier (BBB) was determined by measuring the rate of extravasation of 
3kDa Texas-Red dextran from the vasculature into the tissue. Leukocytes were stained 
using an intravenous injection of Rhodamine 6G and leukocyte interactions, an indicator 
of inflammation, were counted in venules ranging in size from 45 to 90μm. Staining for 
vascular endothelial growth factor (VEGF) and glial fibrillary acidic protein (GFAP), a 
marker of astrocytes, was also performed.  
 
Our studies show that the presence of the tumor alone caused quantifiable changes 
in BBB permeability, and caused an increased in vascular endothelial growth factor 
(VEGF) protein expression in the peritumoral region. Astrogliosis, an increase in reactive 
astrocytes associated with inflammation, was detected in the peritumoral region and 
contralateral to the tumor.   
 
RT of the implanted tumors caused a significant increase in BBB permeability 
and in adhered leukocytes in the peritumoral region, compared to the sham implant 
group.  In addition following RT, VEGF increased both in the peritumoral region and in 
the middle of the tumor. Astrogliosis was also significantly higher in the tumor implant + 
RT animals compared to sham and tumor implanted animals. At 66 days post tumor-
implantation the RT the BBB permeability and astrogliosis were still significantly higher 
compared to sham implanted animals.  
 
We have also evaluated thalidomide as a potential anti-angiogenic/anti-
inflammatory agent with the prospective to protect normal tissue and have shown that it 
had limited effects in a rat C6 brain tumor model and it interfered with RT tumor 
treatment efficacy. In addition, at 66 post tumor implant there was a significantly higher 
v 
incidence of astrogliosis, BBB permeability, and adhered leukocyte counts in the animals 
treated with thalidomide compared to sham implanted animals.   
 
In this work, we have developed and characterized a new rat radiation brain tumor 
model to study the effect of a brain tumor and RT on the normal brain tissue at acute and 
late time points. We have quantified the effect of tumor presence on the peritumoral 
microvasculature and observed a significant increase in vascular permeability but no 
significant effect on leukocyte interactions. The lack of leukocyte interactions might 
indicate that the increase in permeability is associated with the angiogenic signaling 
induced by tumor presence. In support of this conclusion, we observed an increased 
VEGF expression in the peritumoral region. The combination of RT and tumor presence 
had a greater damaging effect on peritumoral BBB integrity measured by an increase in 
leukocyte interactions and permeability which could not be inhibited by using 
thalidomide. Furthermore, the regression of tumor after RT and the achievement of 100% 
survival at 65 days post implant have allowed us to investigate late radiation damage.  
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CHAPTER 1. OBJECTIVE 
 
 
Radiation therapy is one of the principal treatments for brain tumor patients. The 
therapeutic ratio of RT is limited by damage to the normal tissue. Our ultimate goal is to 
eliminate the side effects of cranial irradiation in order to improve the quality of life for 
patients after RT and possibly allow radiotherapists to increase RT dose. The purpose of 
this study was to characterize the effects of radiation in a more clinically relevant rat 
brain tumor model to determine if the presence of tumor renders the tissue more 
susceptible to damage by RT and to evaluate whether thalidomide can limit radiation 
toxicity to normal tissue without interfering with RT treatment efficacy. 
 
 
1.1  Specific Aims 
 
(1) Establish a rat brain tumor model in combination with the cranial window 
technique.  
 
(2) Characterize the effects of RT in the rat brain tumor model using intravital 
microscopy and histopathology at early time points post-RT (10 and 15 days post-
surgery).    
 
(3) Investigate whether thalidomide could be used concomitantly with RT to limit the 
adverse side effects of radiation on normal tissue toxicity using our rat brain 
tumor model at early and late time points post-RT (10, 15, and 65 days post-
surgery) using intravital microscopy.     
 
 
1.2  Hypothesis 
 
(1) Tumor growth has an adverse effect on the peritumoral BBB through the 
angiogenic/inflammatory environment it creates rendering it susceptible to further 
damage by RT. 
 
(2) Thalidomide treatment administered concomitantly with RT will protect the 
normal tissue from RT-induced side effects at early and late time points post RT 
and due to its anti-angiogenic properties it will increase RT efficacy of the tumor.   
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CHAPTER 2.  INTRODUCTION 
 
 
2.1 Brain Tumors  
 
 There are two types of brain tumors: primary brain tumors which originate from 
cells already in the brain, mainly glia cells such as astrocytes, oligodendrocytes, and 
ependymal cells,1 and metastatic brain tumors which are secondary tumors created from 
tumor cells that have traveled from other cancerous tissue located elsewhere in the body. 
Half of all brain metastases originate from lung cancer, 15-20% from breast cancer and 
10% from melanoma skin cancer.2 Metastatic brain tumors are more prevalent than 
primary tumors and approximately 98,000 to 170,000 new cases of metastatic brain 
tumors are diagnosed in the United States each year.3,4 From the 51,410 cases of primary 
brain tumors diagnosed in 2007,  only about 20,500 were malignant.5 Although the 
origins of brain tumors can be different, their treatment is similar. In general, both receive 
radiation therapy.  
 
 The etiology of primary brain tumors is not known. However, epidemiological 
studies show that males have a 40% higher risk for developing a glioma than females. 
High doses of radiation to the brain increase the risk of glioma, meningioma, and nerve 
sheath tumors. The possibility of malignant glioma formation is increased in patients with 
genetic syndromes such as types I and II neurofibromatosis, Li-Fraumeni syndrome, and 
Turcot’s syndrome. They are recorded in 5% of all malignant glioma cases.6 In addition, 
similar to other types of cancer, the tumor suppressor genes are mutated in brain tumors, 
such as, the phosphatase and tensin homolog and the P53 genes.6  In general, patients 
with malignant brain tumors are assumed to have accumulated genetic abnormalities. 
These abnormalities affect detoxification, cell-cycle regulation, and deoxyribonucleic 
acid (DNA) repair mechanisms in the brain, which could lead to tumor development.  
Two common pathways have been identified in primary brain tumors: the ras mitogen-
activated protein kinase pathway and the phosphatidylinositol 3 kinase pathway.7 An 
abnormality in one of the pathways or in one of the genes will most likely not result in a 
brain tumor. It is the accumulation of abnormalities that increases the risk of increased 
cellular growth and hence of tumor initiation. 
 
 Angiogenesis, the process of new vasculature growth from pre-existing vessels, is 
a hallmark of tumors. This continuous expansion of the vascular network is necessary for 
tumor growth. There are three stages of vascular development during tumor progression. 
The first stage is during the early phases of tumor growth when the tumor co-opts 
existing vessels for its growth. In this stage existing vessels become more permeable to 
allow for increased delivery of nutrition to cope with the increased demand by the fast 
growing tumor mass. This process also weakens the basement membrane of existing 
vessels in preparation for vascular sprouting. However, as the tumor reaches a size of 1-2 
mm3,  the existing vasculature is no longer adequate to handle its growth demands.8 It is 
during the second stage, when the rapid tumor growth results in a shortage of oxygen 
supply that the tumor microenvironment experiences an increase in hypoxia and the 
formation of an acidic milieu which tumor cells can tolerate while normal cells cannot. 
2 
This environmental advantage provides tumor cells with a competitive edge over normal 
cells and initiates a rapid growth phase that increases the demand for vascular formation 
resulting in the production of growth factors, such as vascular endothelial growth factor 
(VEGF), that induces angiogenesis.9 The vessels of the new vascular networks are 
dilated, higher in density, chaotic, immature, and tortuous.10 The rapid increase in VEGF 
production does not allow the neo-vessels to mature into normal vasculature but instead 
results in vessels that are leaky because they lack a basement membrane and have 
decreased pericyte coverage. The third, and final stage of vascular development is caused  
by the extravasation of serum, plasma proteins, and blood cells from the dense network of 
leaky vessels, resulting in the formation of edema and an increase in the tumor interstitial 
pressure.11 This increase in interstitial pressure can cause vasculature to collapse 
perpetuating a cycle of increased hypoxia and acidic environment, which can also lead to 
necrotic areas in the tumor.12,13,14 In brain tumors, the increase in permeability associated 
with angiogenesis creates numerous problems during treatment. The first of these is 
caused by the excessive edema and results in the inability to accurately image the tumor 
margin. This in turn affects the volume of tumor and normal tissue irradiated. The 
increase in tumor permeability leads to an increase in the interstitial pressure within the 
tumor which together with the blood-brain barrier (BBB) further hinders the delivery of 
chemotherapeutics to the tumor. Furthermore, the edema affects the oxygenation levels in 
and around the tumor decreasing the efficacy of radiation therapy. Finally the tightly 
regulated homeostasis of the brain is disrupted by the extravasation of serum, plasma 
proteins and cells from the blood system, further weakening the whole organ.  
 
 Inflammation is reported to play a role in angiogenesis. However, this role is 
unclear and seems to depend on tumor cell origin, location, and stage of growth.15-18 
Gliomas have been shown to upregulate a host of inflammatory mediators such as tumor 
necrosis factor (TNF), interleukin-8 and -6, hypoxia-inducible factor-1α, and tumor 
growth factor-β.19,20 There has been some evidence that TNF can promote tumor growth 
through stabilization of angiogenic factors and promotion of cell proliferation and 
induction of inflammation.15,21 TNF knockout mice have shown resistance to skin 
carcinogens22 and TNF receptor-1 knockout mice had a significant decrease in the 
chances of developing liver metastasis of colon cancer.23 Several anti-TNF agents have 
been studied for their anti-tumor activity including infliximab, thalidomide, and 
lenalidomide.24-26 Recent studies show that inflammation precedes VEGF mediated 
angiogenesis and acts to increase leukocyte extravasation and permeability of the BBB in 
rats.27 The increase in permeability has been shown to be caused, in part, by the 
formation of endothelial fenestrations (vesicles).28,29 Inflammation in different diseases 
has been shown to increase vesicular activities.30,31 Lossinsky et al.32 have shown that 
intracellular adhsion molecule-1 (ICAM-1) is present within the inner membrane of 
vesicles in developmental and tumor tissues. The expression of ICAM-1 has also been 
shown to occur following treatment with VEGF and is proposed to be part of the 
preparatory step towards angiogenesis.33,34 
 
 Treatments to shut down this angiogenic process are already in clinical trials.35,36 
Anti-angiogenic therapies work by normalizing the tumor vasculature by pruning the 
immature vasculature resulting in better blood flow within the tumor. Normalized 
3 
vasculature within a tumor would result in better tumor oxygenation, increasing the 
efficacy of radiation, and would allow for better delivery of therapeutics. Bevacizumab, a 
monoclonal antibody to VEGF-A, is the first U.S Food and Drug Administration 
approved anti-angiogenic inhibitor for use in metastatic cancers such as colon, non-small 
cell lung, and breast cancer. It is also undergoing clinical trials in non-metastatic colon 
cancer, non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, 
ovarian cancer, hormone-refractory prostate cancer, non-metastatic unresectable liver 
cancer and metastatic or unresectable locally advanced pancreatic cancer.  
 
 
2.2 Understanding of the Peritumoral Region 
 
The peritumoral region refers to the area surrounding the tumor. It is an 
amorphous region that is hard to define. Consequently, the peritumoral region is defined 
in different terms in imaging studies. Provenzale et al. defines it as the “hyperintense area 
seen on T2-weighted MR images that surrounded the region corresponding to the 
enhancing area seen on the T1-weighted MR images”.37 Julien et al. defines it as “the 
region at the edge of the tumor having the largest [blood volume] due to a high vessel 
density” using magnetic resonance imaging (MRI).38 Nevertheless, the microenvironment 
of the peritumoral region is of interest because it is the interface between normal tissue 
cells and tumor cells. Understanding the influence of the tumor cells on the 
microenvironment of this interface may lead to therapies that could aid in the fight 
against tumors. Further, the peritumoral region is the common site of tumor invasion. In 
gliomas, the invasion of the tumor cells into the normal tissue is a consequence of the 
degradation of the extra cellular matrix (ECM) by proteolytic enzymes expressed by the 
tumor cells. The in vivo studies of Sandstrom et al. have shown that glioma tumors 
exceeding a size of 10 mm3 both tissue plasminogen activators mRNA and urikinase 
plasminogen activator mRNA, (both precursor to plasmin which is a protease) were 
expressed at the edge of the tumor and branched into the normal brain.39 In addition, 
VEGF mRNA expression was found in the peritumoral border of tumors larger than 10 
mm3.39 Other proteases have also been associated with glioma cell invasion. Guo et al. 
have shown that  angiopoietin-2, a protein growth factor, is co-overexpressed with matrix 
metalloproteinase-2, and membrane type 1 matrix metalloproteinase (matrix 
metalloproteinases that are involved in ECM degradation and remodeling) in invasive 
areas of human primary glioma specimens.40  
 
 Currently the standard of care for the majority of brain tumors is surgical 
resection when feasible. The tumor area to be resected is primarily based on computed 
tomography (CT) and MRI. A major problem with tumor resection is the difficulty in 
defining the boundary between the tumor and normal tissue, which introduces uncertainty 
in the resected volume.41 Uncertainties in demarcating the boundary between normal and 
tumor tissue related to edema (with and without resection) makes the planning of 
radiation therapy difficult i.e, to draw the dosage map without under or over estimating 
the irradiation region. Underestimating the gross tumor volume (GTV) can lead to tumor 
cells not being irradiated and can increase the chances of tumor reoccurrence.42 Over 
estimating the GTV can lead to unnecessary irradiation of the normal tissue that can lead 
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to long-term detrimental effects. A clear characterization of the peritumoral region may 
help clinicians in more accurate demarcation of the tumor and normal tissue boundaries 
leading to improved resection and radiation mapping.  
 
 During radiation therapy, patients are repeatedly examined by imaging techniques 
to evaluate the progression of the cancer. Edema during and following radiation therapy 
can inhibit the clinician’s ability to evaluate the efficacy of treatment. Following 
radiotherapy, 40% of gliomas are typically enhanced when imaged with MRI; and of 
these cases, 50% are due to an increase in vessel permeability resulting from radiation 
which improves over time.6 The apparent increase in tumor size can mask actual 
progression of the tumor which may not have responded to radiation treatment.  
 
 Brain tumors, especially gliomas, frequently present peritumoral edema which is 
commonly treated with corticosteroids such as dexamethasone.43 The use of 
corticosteroids can lead to Cushing’s syndrome caused by high levels of cortisol in the 
body, can cause symptoms ranging from central obesity to neurological or psychiatric 
syndromes. Cushing’s syndrome is treated by tapering the amount of steroids given, but 
if left untreated it can lead to cardiovascular disease and increase mortality. Patients using 
corticosteroids are also at higher risk of Pneumocystis jiroveci pneumonitis, acute 
corticosteroid myopathy during treatment, and long term complications of chronic 
corticosteroid myopathy, osteoporosis, and compression fractures.43,44 The discovery of 
new therapies to treat peritumoral edema may allow for a reduction in the use of 
corticosteroids.  
 
 
2.3 Radiation 
 
 
2.3.1 Radiation Planning 
 
In the process of treatment planning, the oncologist first defines the clinical target 
volume (CTV) which consists of the tumor delineated on radiological scans, gross tumor 
volume (GTV), plus a 1cm margin to account for any microscopic tumor spread (some 
protocols use a 2 cm margin).42 Next the oncologist defines the planning target volume 
(PTV) which includes the CTV plus a ½ cm margin45 that takes into account inaccuracies 
such as patient movement and differences in patient positioning in repeated imaging 
examinations (Figure 2-1). Therefore, the irradiated volume includes not only tumor 
tissue, but also peritumoral tissue (combination of tumor and normal tissue) and normal 
tissue (Table 2-1). The radiation regimen for primary malignant tumors is from 60Gy up 
to 80Gy of partial-field external beam irradiation in fractions between 1.8Gy and 2.0Gy 
(5days/week).6 The radiation regimen for metastatic brain tumors is different due to the 
diffuse nature of metastatic tumors and the common occurrence of more than one tumor. 
Therefore, the majority of patients with metastatic tumors receive whole brain 
radiotherapy with a standard regimen of 30Gy in 10 fractions over 2 weeks.2  
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Gross Tumor 
Volume (GTV) 
Clinical Target Volume 
(CTV) 
 
CTV=1cm+GTV 
Planning Target Volume 
(PTV) 
 
PTV= 0.5cm+CTV 
 
 
 
Figure 2-1. Schematic of a tumor cross section to illustrate the determination of the 
planning target volume which is composed of the gross tumor volume, and an 
additional 1.5 cm margin.  
 
 
 
 
 
 
 
 
 
 
Table 2-1. The gross tumor volume (GTV) and planning target volume (PTV) of 
three different spherical tumors.  
 
Tumor 
Diameter 
(cm) 
Gross Tumor 
Volume  
(GTV) 
 (cm3) 
Planning Target 
Volume  
PTV = GTV + 1.5 cm 
(cm3) 
Ratio of 
PTV/GTV 
Percentage of 
PTV compared 
to the brain 
(assumed as 
1200cm3) 
2.5 8.18 87.11 10.65 7.26% 
3.75 27.61 161.03 5.83 13.41% 
5.0 65.45 268.08 4.10 22.34% 
 
The ratio of PTV/GTV has been calculated to demonstrate how much the PTV adds to 
the GTV. Note the larger PTV/GTV ratio for the smallest tumor volume and the 
percentage of brain targeted to receive radiation compared to brain volume (assumed to 
be 1200 cm3).  
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2.3.2 Radiation Side Effects 
 
  Radiation toxicity in humans is usually organized chronologically as: acute 
(within days), early (1-6 month post treatment), and late toxicity.46 Late-term effects are 
common in tissues with limited potential for self-renewal, such as in the central nervous 
system (CNS).47 Radiation side effects in the brain are further amplified by the effects 
related to surgical resection, chemotherapy, patient age, tumor size and location.47 
Radiation toxicity of the CNS can be identified by several markers. Apoptosis is one of 
the early effects of RT together with astrogliosis, BBB damage and the inflammatory 
cascade that occurs in the acute phase following RT. Transient demyelination is observed 
between one and three months following RT and is usually accompanied by 
oligodendrocyte damage. Impairment of neurogenesis and depletion of progenitor cell 
populations occurs at all times following RT. Finally late vasculopathy, necrosis and glial 
atrophy are hallmarks of late radiation damage and signs of treatment morbidity.48,49 This 
chronological division of radiation injury does not necessarily reflects a mechanistic 
disparity50 however, early events may initiate a cascade of events leading to the observed 
changes.  
 
 
2.3.3 Radiation Damage 
 
Radiation therapy is one of the principal treatments for brain tumor patients. As 
the high-energy x-ray photons travel through tissue, their primary interaction with the 
atoms and molecules of the tissue is through Compton scattering.51 The result of such 
scattering is the emergence of an electron and photon, roughly dividing the original 
photon energy and moving in almost the same direction. This process continues, now 
with more vigor because of the freed electrons, initiating an avalanche of free electrons 
that proceed to ionize atoms along its path. The newly formed ions produce free radicals 
that can interact chemically to alter or destroy important protein structures or DNA 
strands damaging or destroying the cells affected. Ionic interactions are strongly 
dependent on the ion’s mass, and the most lethal of such ions are those formed through 
the ionization of water, or oxygen, molecules. There are two types of radiation damage; 
direct damage, and indirect damage. Direct damage is defined as damage to one of the 
chemical bounds of a deoxyribonucleic acid (DNA) molecule through interaction with an 
X ray or gamma photon of the radiation therapy. Indirect damage from radiation is a 
result of free radical production within the cell and the damage to the DNA molecules 
due to their interaction with these radicals. Since water is in high abundance in the human 
body, 70% to 80%, the majority of free radicals formed are a result of radiolysis of water. 
Due to the short life time of free radicals, ~10-10 seconds, only free radicals generated 
from water molecules can damage DNA molecules located within 2-3nm distance. Direct 
or indirect damage can result in breaks in a single strand of DNA, in both strands at 
separate locations (not close to each other), and/or in double strand breaks of DNA 
relatively close in proximity. The first two types of damage, single strand breaks and 
double stranded breaks at separate locations, have little biological consequence on the 
cell and are not lethal. Double strand breaks occurring in close proximity, as a result of 
radiation exposure, are responsible for cell killing, mutation, and carcinogenesis.51 Since 
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cancerous cells divide more rapidly than most normal cells, probability that cancerous 
cells will interact with destructive radicals during their mitotic phase when they are most 
vulnerable to damage is much larger than for normal cells. One of the major 
predicaments in RT is that oxygen abundance is beneficial for the formation of free 
radicals which cause damage to the tumor cells but in general the tumor 
microenvironment is hypoxic and lacks the normal levels of oxygen.9 
  
 Radiation damage has also been hypothesized to be induced, in part, by the 
bystander effect. The bystander effect is a term that encompasses the biological effects 
seen in non-irradiated cells resulting from exposure to irradiated cells. Numerous inter- 
and intra- cellular pathways have been shown to contribute to the bystander effect in 
cells. DNA mutations have been found in bystander cells upon exposure to other 
irradiated cells or growth media from these cells. The growth media may induce 
bystander effects because it has been shown that irradiated cells secrete tansforming 
growth factor-α and TNF-α which can cause mutagenesis, decrease survival, and 
modulate the expression of cell cycle-related genes.52 Other possible explanations of the 
bystander effect are related to increases in intracellular ROS (reactive oxygen species) 
and Ca2+ levels.53 Bystander effects have been noted with cell to cell distances as large as 
of 7.5 mm. However, the spatial extension of the bystander effect is not lucid and 
apparently depends on the type of culture and the measurement used.54,55 In vivo the 
bystander effect, measured by RAD51 upregulation, was detected at more than 1 cm of 
distance from the irradiated tissue.56 The exact mechanisms responsible for the bystander 
effect are still unknown and further research will provide a better understanding of this 
phenomenon and its consequences. 
 
The sensitivity of organs and/or cells to radiation is dependent on a numerous 
factors such as dose of RT, time between RT fractions, rate of cellular division, 
differentiation of tissue, and the volume of organ irradiated. One major factor is the 
percentage of the cell population undergoing G2 phase and mitosis phase of the cell 
separation when cells are most sensitive to radiation, according to the the Bergonie-
Tribondeau Law.57 The increased sensitivity in the G2 phase is related to its short 
duration and thus the cell does not have enough time to repair damaged DNA. The 
sensitivity of cells to radiation during mitosis is increased because the probability of 
lethal mutations is larger since damaged DNA cannot be repaired during division. This is 
the reason why tumor cells, which have very high proliferation rates, are more sensitive 
to radiation than the majority of normal cells in the body. Another factor is the degree of 
cell differentiation in the organ. The more differentiated the cell population the less 
sensitive the organ is to radiation. This phenomenon is again related to the cell cycle. The 
more differentiated cells are usually the less proliferative thus the probability that cells 
are in either the G2 or mitosis phases is smaller than for less differentiated cells. In 
addition, organs with cell populations that are not fully differentiated result in increased 
damage because the cells that are lost are potential progenitors of other cells causing a 
decrease in cell population related to cell death and the potential offspring the cells would 
have produced. For example when stem cells are lost it can be very damaging because 
stem cells are responsible for replenishing the cell populations. The rate of cellular 
turnover in tissue effects when RT damage becomes evident. In tissues with high 
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turnover rates the RT damage can be recognized early. An example of this type of tissue 
would be the intestinal epithelium or bone marrow.57 In tissues with slow turnover, the 
number of cells damaged is decreased due to the smaller number of cells in mitosis, and 
the number of offspring they produced is few. Therefore damage is not evident until later 
time points.  The brain is a good example of an organ with this quality.  
 
 
2.4 Brain Irradiation 
 
 The brain is a unique organ. It controls the central nervous system and is 
functionally responsible for coordinating movements, senses, consciousness, and 
production of certain hormones.58 Following radiation treatment, brain tumor patients 
suffer from long-term side effects such as memory loss, fatigue, and decreased 
attention/concentration.59 These side effects can be attributed to physical changes in the 
brain such as demyelination, necrosis, vasculopathy, and astrogliosis seen at late time 
points. The exact nature and cause of this late term damage is still not clear but two main 
theories are currently being researched.  
 
 
2.4.1 Vascular Theory: Endothelial Cells 
 
This theory advocates that late term damage in the brain is caused by early 
damage to the vasculature of the brain. The microenvironment of the brain is regulated 
and protected by specific barriers, which include the vascular-endothelial barrier (referred 
to as the BBB) at the capillary-parenchyma interface and the epithelial barrier (blood-
cerebrospinal fluid barrier) at the choroid plexus.60 The BBB is more than a physical 
barrier: it plays a fundamental role in regulating the movement of substances between the 
blood and the CNS, see Figure 2-2. The microvascular network is defined as a series of 
interconnected arterioles, venules, and capillaries with low Reynolds numbers and large 
surface areas which provide an optimal environment for the supply of oxygen, nutrients, 
removal of waste products and interaction of blood cells (i.e., red blood cells, white blood 
cells, platelets, etc.) with endothelial cells (ECs).61,62 The overall design of the 
microvascular network is a function of metabolic stimuli, biochemical growth factors, 
feedback control, external stimuli, and hemodynamic parameters.63 The microvascular 
network is also the site of the BBB, and the endothelial cells that make up the 
microvascular network-barrier contain few pinocytotic vesicles and adhere to each other 
via tight junctions (TJ)64 which are formed by junction-specific proteins such as occludin. 
TJ limit paracellular transport of hydrophilic compounds into the CNS as compared to 
non-CNS vessels.65,66 Damage to the endothelial cells compromises the integrity of the 
BBB. Also, astrocytes in close proximity to the endothelial cells add another impediment 
to paracellular transport by biochemically conditioning the endothelial cells and 
strengthening the TJ between them.67 The ECs also play an important immune function 
through leukocyte surveillance and extravasation by regulating adhesion integrins and 
cytokine production.68 In particular, they have been shown to directly secrete TNF.69 This 
complex vascular network is essential to supplying the brain with nutrients and helps to 
maintain the homeostasis of the brain. 
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Figure 2-2. A cartoon depicting a cross section of brain parenchyma showing the 
structure of the blood brain barrier (BBB) and the damage induced by radiotherapy 
(RT) of brain tumors.  
 
(A) Normal BBB showing: intact tight junctions (TJ); lack of vesicles; astrocytes and 
pericytes abutting the endothelial cell (EC) providing additional barrier support; neuron 
with thick, healthy myelin. (B) Damaged parenchyma; astrocytes and pericytes have 
pulled away from the EC; leukocyte has adhered to the EC; loss of TJ integrity; and 
vesicle formation. The damage to the BBB resulted in molecule extravasation out of the 
blood vessel and into the extracellular space. Further, neurons show signs of damage 
which resulted in thinning of their myelin increasing demand for energy (for signal 
transmission) resulting in the swelling of the mitochondria. 
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 When the barrier between the vascular supply of the brain and the CNS 
parenchyma is disrupted, excess extravasation of proteins, biologic-response molecules 
(e.g. growth factors, cytokines, and clotting factors), inflammatory cells, and therapeutic 
drugs can damage the brain.60,70-72 The disruption of the BBB has been identified as a 
consequence of various diseases/injuries such as multiple sclerosis, ischemia, human 
immunodeficiency virus, hypertension, brain tumors, CNS injury and radiation 
exposure.72-76 In these diseases, the inflammatory cells are able to penetrate the BBB and 
destroy the myelin surrounding the axons. Demyelination and myelin thinning have been 
reported in the CNS following RT.77-80 Felt et al. have shown that RT-induced BBB 
permeability prolongs induced demylination of neurons.81,82 One of the major adverse 
effects of brain tumor irradiation is the increase in BBB permeability following RT. In 
agreement with others, we83-86 have demonstrated there is an increase in BBB 
permeability following RT. This increased permeability is caused in part by EC damage, 
as expressed by changes in tight junction integrity, and by vesicle formation post-
irradiation. RT-induced EC damage has been investigated by several scientists87-89 aiming 
to elucidate the effect of RT on initiating and/or sustaining radiation side effects. Eissner 
et al.,90 as well as others,88,89 have shown that irradiated ECs both in vitro and in vivo 
undergo apoptosis at a higher percentage than other cells. Our studies using electron 
microscopy showed that RT damages TJ,84 which is connected to the increase in BBB 
permeability. In addition, several studies, including our own, have shown an increase in 
BBB permeability and an increase in the number of vesicles following fractionated 
cranial irradiation.84-86 RT has been shown to induce changes in the microvasculature 
which in turn have a marked effect on tissue oxygenation and could lead to the 
development of acute and/or chronic hypoxia.91 Ansari and Gaber et al. have shown that 
brain irradiation causes a reduction in tissue oxygenation, as measured by EF5 (a 
pentafluorinated derivative of etanidazole) staining.92 Hypoxia has been shown to 
activate inflammatory mediators, and the inflammation marker ICAM-1 on ECs93,94 and 
to promote angiogenesis by upregulating VEGF and its receptors.9 Hypoxia also plays a 
role in the tumor’s radio-resistance caused by the shortage of oxygen available to produce 
reactive oxygen species (free radicals are in large part responsible for the destruction of 
DNA by ionizing radiation) (Figure 2-3).95-98 
 
The damage to the microvasculature and the breach of the BBB related to RT can 
also disturb the delicate brain microenvironment through exposure of the brain 
parenchyma and neural cells to noxious substances.76,84,97 An imbalance in the brains 
microenvironment can set a chain of events into motion (such as the release of 
cytokines), magnifying the original signal, and contributing to late-term tissue damage 
which might play a role in cognitive impairment.99 In this study we have used BBB 
permeability as a measure of radiation damage at early and late time points. In addition 
we have also measured the degree of leukocyte-endothelial interactions as a measure of 
inflammation. 
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Figure 2-3. Flowchart of the sequences of events following cranial irradiation. 
 
Two of the main events that occur following exposure to radiation are apoptosis of cells 
and inflammation, which then can lead to parenchymal and blood brain-barrier (BBB) 
damage in the brain.  
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2.4.2 Glial Theory: Oligodendrocytes/O-2A Progenitor Cells  
 
The glial theory attributes the late term side effects of radiation to the loss of 
oligodendrocytes in the brain. Oligodendrocytes are responsible for producing and 
repairing the myelin sheaths which insulate the axons in the brain, and therefore, the loss  
of oligodendrocytes can lead to demyelination of axons. The decline in oligodendrocyte 
cell population after radiation has been attributed to the loss of oligodendrocyte precursor 
cells, O-2A progenitor cells. Following radiation exposure O-2A precursor cells can lose 
their ability to reproduce and may undergo apoptosis therefore limiting the number of 
progeny produced.100 In addition, it has also been shown that oligodendrocytes undergo 
apoptosis following radiation, which may be a result of direct/indirect radiation damage 
and possibly the changes in oligodendrocyte microenvironment such as BBB 
breakdown.46,87,101 
 
 
2.4.3 Effects of RT on CNS Cells: Astrocytes, Microglia, Neurons and Subependymal 
Cells 
 
Astrocytes are a subtype of glial cells and are the most common phenotype in the 
brain. Astrocytes have numerous functions such as calcium signaling, neurotransmitter 
function, cytokine secretion, and structural support of the BBB. RT damages astrocytes in 
the brain. We and others have reported activated astrocytes after treatment with 
fractionated irradiation.84,91,102 Astrogliosis (or gliosis), the up-regulation of astrocytes 
present in an area of the brain is induced by a host of inflammatory mediators. Prolonged 
gliosis can create glial scar sites which have been theorized to inhibit axonal regeneration 
or remylination.103,104 Whether RT-induced gliosis is caused by direct ionization damage 
or due to the breach in the BBB exposing the parenchyma to noxious substances and 
inflammatory cytokines is unclear. However, activated astrocytes have been shown to 
secrete inflammatory agents105,106 which, could contribute to EC and microvascular 
damage and have detrimental effects on oligodendrocytes and O-2A progenitor cells. In 
this study we have used the degree of astrogliosis as an inflammation marker resulting 
from irradiation. The advantage of using astrogliosis as a marker of damage is that it is 
seen both in the parenchyma and BBB damage and therefore it is not biased. 
 
 Microglia are the brains immune defense cells which are involved in local 
inflammatory response, phagocytoses and can produce and secrete hydrolytic enzymes, 
lipid metabolites, and oxygen radicals. It has been shown that following irradiation the 
number of microglia increased and became activate,46,107 in addition, microglia have 
close functional relationships due to their ability to recruit each other and communicate 
through extracellular signaling. However the exact role microglia have in radiation-
induced damage is unclear. 
  
 Neurons are the cells in the brain that transmit and process signals through 
electrochemical signaling. Most likely neurons do not contribute to radiation-induced 
damage in the brain. Studies in vitro and in immature rats have shown that following 
radiation there was death of neurons through apoptosis but these results could not be 
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duplicated in adult animals. It is believed that astrocytes protect the neurons after 
radiation. In vivo studies have shown that the radioresistance of neurons increased in 
coculture with astrocytes and in astrocyte-conditioned media possibly through their 
ability to take up extracellular glutamate or through their catalase activity which protects 
against H2O2, a byproduct radiolysis of water.46  
 
 In the subependymal (SE) area of the brain there are stem cells which are the 
source of neurons, astrocytes, and oligodendrocytes in the brain. SE cells are able to 
migrate within the brain and differentiate into a variety of brain cells. The function of the 
SE cells has been hypothesized to be a reserve of undifferentiated cells capable of being 
recruited after insult to the brain. An in vivo study demonstrated that induced 
demyelination in a mouse resulted in SE cells migrating to the injured site and 
differentiating into myelin-like structures.108 Hopewell et al.109 has shown that there is a 
dose dependent loss of SE cells following radiation, but a cause-and-effect relationship 
has not been established between late effects of radiation and SE cell loss.  
 
 
2.5 Thalidomide  
 
Thalidomide is a derivative of glutamic acid which has anti-inflammatory and 
angiogenic activities. It inhibits the production of TNF, cycloxygenas-1 and -2, VEGF, 
and decreases the binding activity of nuclear factor –kappa B (NF-κB).110,111 The 
mechanism by which thalidomide aids in control of tumors is not known. There have 
been 16 clinical trials on thalidomide of which 15 were phase II and one was phase III. In 
a phase II trial for the treatment of recurrent glioblastoma, Groves et al. showed that the 
combination of temozolomide and thalidomide was safe but provided little improvement 
of tumor control over temozolomide alone.112 In addition, numerous studies have 
reported thalidomide toxicity what resulted in patient death, discontinuation of treatment, 
and patients dropping out of the studies. Thalidomide is a small molecule113 that can 
cross the BBB in therapeutic quantities and has been shown to significantly increase 
survival rate and decrease motor neuron cell death in transgenic mice with amyotrophic 
lateral sclerosis symptoms.114  
 
In this study we have chosen thalidomide as a potential therapeutic to minimize 
radiation-induced damage to the normal tissue due to its ability to reduce TNF levels 
which we have studied in the past using a mouse model.91 Thalidomide is widely 
available U.S Food and Drug Administration approved and currently in numerous phase 
II studies. In addition, thalidomide has the ability to cross the BBB which means it may 
be able to protect the brain parenchyma in addition to the vasculature from radiation 
induced damage (Figure 2-4). 
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Figure 2-4. Cartoon depicting our hypothesis that the combined effect of tumor 
presence and radiation therapy (RT) induces an inflammatory and angiogenic 
environment that initiates normal tissue damage. 
 
This new environment is characterized by an increased TNF, NF-κB, and VEGF 
expression, leukocyte adhesion, and BBB permeability. Treatment with anti-TNF 
treatment (thalidomide) concomitant with RT would block the inflammation following 
RT leading to a reduction in the RT-induced damage to normal tissue. This could allow 
us to reach the maximum biologically effective RT dose. 
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CHAPTER 3.  MATERIALS AND METHODS 
 
 
3.1 Culture 
 
 Rat glioma cells C6 (American Type Culture Collection, Manassas, Va) were 
transfected to express green fluorescent protein (GFP) and obtained from Dr. Duntsch’s 
laboratory at the University of Tennessee, Health Science Center. Cells were monolayer 
cultured in 75cm2 flasks and maintained in Ham's F12K medium with 2 mM L-
glutamine, supplemented with 15% Horse serum, 2.5% Fetal Bovine serum and 1% 
penicillin-streptomycin at 37°C in humid air containing 5% CO2.  
 
 
3.2 C6 In Vitro Experiments 
 
C6-GFP cells were plated per well at a concentration of 2x105 cells in 25cm2 
flasks 72 hrs prior to RT. There were five groups of cultures: control cells (underwent 
transportation to the irradiator), RT-only (8Gy), and RT + Thalidomide (8Gy of 
irradiation and 3 different concentrations 1µg/ml, 10µg/ml, and 100µg/ml of media).  
 
 
3.2.1 Viability Assay 
 
At 48, 72, and 96 hrs post treatment the cells and supernate were removed from 
the flask using 0.25% trypsin mixed with 1:1 ratio with trypan blue 0.4% solution and 
were counted 5 minutes later using a hemocytometer. 
 
 
3.2.2 Cell Proliferation 
 
At 48, 72, and 96 hrs post treatment the cells and supernate were removed from 
the flask using 0.25% trypsin mixed and centrifuged for 5 minutes, at 150 relative 
centrifugal force, 900 rotations per minute. Supernate was removed and cells resuspended 
in 2 mls of phosphate buffered solution and counted using a hemocytometer.  
 
 
3.3 Animal Studies 
 
Male Wistar rats 6-8 weeks were obtained from Harlan (Indianapolis, IN). Rats 
were anesthetized using isoflurane/oxygen mixture followed by an intraperitoneal (i.p.) or 
intramuscular (i.m.) injection of a ketamine and xylazine mixture (87/13mg/kg 
respectively) at a dose of 1ml/kg body weight (Henry Schein, Melville, NY). Female 
athymic CD1 nu/nu mice (8 to 10 weeks of age) were purchased from Charles River 
Laboratories (Wilmington, MA) for use in the study. Mice were anesthetized using 
isoflurane/oxygen mixture followed by an i.p. or i.m injection of a ketamine and xylazine 
mixture (50/50mg/kg respectively) at a dose of 1ml/kg body weight (Henry Schein, 
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Melville, NY) Animal studies were done in accordance with guidelines established by the 
University of Tennessee, Health Science Center Institutional Animals Care and Use 
Committee.  
 
 
3.4 Radiation  
 
Animals were irradiated using cesium irradiation (Mark 1 Model 25 irradiator, JL 
Shepard and Associates, CA) at the VA Medical Center in Memphis TN. Briefly, animals 
were anesthetized and then secured to a chamber that was then placed inside the 
irradiator. The radiation was localized to the cranial region (width of 1cm) using a model 
335 collimator (JL Shepard and associates, CA) that collimated the radiation field to a 
1cm band. Adequate lead shielding was used in the design of the collimator to ensure that 
volumes outside the radiation field received less than 3% of the prescribed dose 
 
 
3.4.1 Cranial Tumor Irradiation  
 
Animals received a hypofractionated regime of 8Gy /day for 5 days starting at 5 
days post surgery for a total of 40Gy. The biological effective dose (BED) of this RT 
regimen is 200Gy which is 1.67x higher than a patient regimen of 60Gy, and 1.25x 
higher than a patient RT regimen of 80Gy(Appendix C). 
 
 
3.4.2 Flank Tumor Irradiation 
 
 All mice received three daily fractions of 8Gy RT (24Gy total) delivered locally 
to the flank tumors using a cesium source starting at day zero i.e., when the tumors reach 
a size of approximately 550mm3 (usually at 11 days post-tumor implantation). A lead 
collimator was used to localize radiation only to the tumor and flank area. 
 
 
3.4.3 C6 Cells 
 
All cells in 25cm2 flask were transported to the VA Medical Center in Memphis 
TN. A stack of 3 flasks were placed at center height (middle flask) inside the irradiator on 
a turntable which rotated during administration of 8Gy of radiation to ensure a uniform 
dose within the flasks.  
 
 
 3.5 Thalidomide Treatment 
 
Racemic thalidomide purchased from Sigma-Aldrich (St. Loius, MO, catalog # 
T144) was dissolved in DMSO (0.1mg of Thalidomide /1ul of DMSO) and was injected 
i.p. (100mg/kg/day) 30 minutes prior to radiation. For in vivo experiments thalidomide 
was diluted with DMSO (0.1mg Thalidomide /1µl of DMSO) and then further diluted 
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accordingly with DMSO until in 1µl there was 100µg, 10µg, and 1µg. Thalidomide was 
added to the cultures 30 minutes prior to irradiation.  
 
 
3.6 Flank Tumor Inoculation 
 
Rat C6-GFP glioma cells were prepared at a concentration of 4 x 106 cells in 
200μl of phosphate buffer saline and injected subcutaneously into the right flank of each 
mouse. The tumor volume was assessed every 3 days using skin calipers for 3 weeks 
using an ellipsoidal tumor volume formula, see Equation 3-1.  
 
Volume = 0.52*(major axis)*(minor axis)2                    (Equation 3-1) 
 
Measurements were made using skin calipers 3, 6 and 9 days following the start of 
treatment.  
 
 
 3.7 Cranial Window Technique 
 
As previously described by Gaber et al.115 animals were anesthetized and placed 
in a stereotaxic frame (Kopf Instruments, Tujunga, CA) with their body temperature 
maintained at approximately 37°C by a silicon-heating mat. The scalp and underlying 
soft tissue over the parietal cortex were removed bilaterally. Then a dental drill was used 
to create a rectangular cranial window that extends from the bregma to the lambdoid 
sutures and centered on the midsagittal suture. The dura mater was then punctured and 
excised using iris microscissors. Using cyanoacrylate glue, a glass plate was fixed to the 
bone surrounding the cranial window. All surgical procedures were carried out using 
sterile techniques.   
 
 
3.8 Cranial Tumor Implantation 
 
C6-GFP cells were implanted in the upper right hemisphere of the brain between 
the bregma and lambda sutures avoiding any visible vessels. C6-GFP cells were prepared 
prior to surgery at a concentration of 2x105 cells/μL of BD Matrigel Matrix (BD 
Bioscience, CA) and placed on ice. A 10µL Hamilton syringe was then used to implant 
1x106 cells in 5µL: 2.5µl of cell mixture and/or matrigel injected at a depth of 2.5 mm, 
1.25μL of the cell mixture and or/matrigel injected, at a depth of 1.5mm in the brain, and 
1.25μL of cell mixture and or/matrigel, and at a depth of 0.5mm (sham implant animals 
had matrigel implanted).  
 
 
3.9 Intravital Imaging 
 
To visualize the cerebral microcirculation, the animals were anesthetized and then 
placed in the stereotaxic frame under the intravital fluorescence microscope. The 
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intravital measurement of BBB permeability was performed on days 11, 16 and 66 post 
implant. Leukocyte-endothelial interactions were performed on days 10, 15 and 65 post 
tumor implant. Images of tumor size were acquired every 5 days post-implant to 30 days. 
(Figure 3-1, Tables 3-1 and 3-2 for experimental design).  
 
 
3.9.1 BBB Permeability Measurement   
 
As previously published by Gaber et al.,83,115 Texas-Red dextran 3 kDa (1% 
solution, 0.4ml/kg) (Invitrogen # D3329) was administered intravenously and used as a 
permeability tracer. Images were made using an industrial-scale microscope (model MM-
40, Nikon) having a digital camera (CoolSnap ES, Roper Scientific) with a 100W 
mercury light source. Images were analyzed using MetaMorph software (Universal 
Imaging Co., PA) to measure the permeability of the brain pial vessels. Two rectangular 
regions of interest (ROI) were chosen in the vessel (restricted to vessels 45-90µm) and in 
the surrounding tissue and their average intensities recorded. Our analysis method 
follows Wu et al.116 and Yuan et al.83 with some modifications. For slow extravasation 
processes, Fick’s law can be used to show that the permeability (P) and the rate of change 
of the tissue intensity due to dye extravasation (dIt  dt) are related.83 
 
                                          
td
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V
I
P t
v
1=                                       (Equation 3-2) 
           It is the tissue intensity, Iv is the initial fluorescence intensity in the vessel, V/S is the ratio 
of vessel volume to surface area.117,118 We limited our calculation of dIt/dt to the time 
period between 30 s and 2 min after tracer injection. During this period, the extravasation 
process was approximately linear, and back flux of the tracer into the plasma 
compartment could be ignored (Figure 3-2 and Equation 3-2). 
 
 
Due to the green fluorescence of the C6 cells, the permeability tracer used was 
Texas-Red dextran to avoid the florescence overlap with the tumor. One major difference 
between the two dyes is their wavelengths. Due to the higher wavelength of Texas-Red, 
about 615nm, the signal is not absorbed by the hemoglobin. As a result, unlike 
flourescein isothiocyanate dextran (FITC) the vasculature will stay fluorescent over a 
long period of time, which could possibly lead to noise in the data from the scatter 
associated with the fluorescent vasculature (Appendix B).  
 
 
3.9.2 Leukocyte-Endothelial Cell Interactions  
 
Rhodamine-6G (Sigma), a lipophillic positively charged molecule that selectively 
stains 99.9% leukocytes mitochondria within minutes of being administered, was injected 
i.v. (0.5% solution) (0.4mg/kg). Adhesion was measured in the same vessels used in the 
extravasation measurement and in the immediate surrounding vessels. A leukocyte is 
considered adhered if it does not move for 30seconds; this measurement is expressed as  
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Leukocyte Interactions 
Permeability Radiation (8Gy/day) 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Time line of the intravital experiments performed in vivo. 
 
Radiation treatment started on day 5 post tumor implant. Measurements of Leukocyte 
endothelial interactions were performed on days 10, 15 and 65 days post surgery. 
Permeability measurements could not be performed on the same days of leukocyte 
endothelial interaction because of the overlap in fluorescence of the dyes used. Therefore 
permeability measurements were performed on days 11, 16 and 66. Tumor surface area 
measurements and bright light images were on days 5, 10, 15 and every 5 days after or 
until no tumor was visible.  
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Table 3-1. Table showing the experimental groups and measurements performed at 
the early time points. 
 
Experimental  
Group 
 
Measurements 
Intravital Microscopy Histology 
Tumor 
size Permeability
Leukocyte 
Interactions
Glial Fibrillary 
Acidic Protein 
Vascular 
Endothelial 
Growth 
Factor 
Sham Implant      
Tumor Implant      
Sham Implant +RT 
(40Gy)      
Tumor Implant + RT 
(40Gy)      
Tumor Implant + RT 
+ Thalidomide 
(40 Gy, 100mg/kg/d 
prior to RT) 
     
 
 
 
 
 
Table 3-2. Table showing the experimental groups and measurements performed at 
the late time points. 
 
Experimental Group 
 
Measurements 
Intravital Microscopy  Histology 
Permeability Leukocyte Interactions  
Glial Fibrillary 
Acidic Protein
Sham Implant  
Tumor Implant + RT 
(8Gy/day, total of 40Gy)     
Tumor Implant + RT + Thalidomide 
(8Gy/day , total of 40 Gy) 
(100mg/kg/day prior to RT)   
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Figure 3-2. A collage showing the process of our intravital microscopy BBB 
permeability measurement. 
 
(A) Picture of a rat with cranial window secured in a stereotaxic frame, (B) the image as 
seen through the cranial window (large white mass is the fluorescent tumor), (C) The 
vasculature following injection of a fluorescent dye, and (D) the average intensity over 
time measured in the tissue and venule.  
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the number of adhered leukocytes per 100µm of vessel length.115 Leukocyte rolling was 
also performed in these vessels. Any leukocytes that is rolling within the 100µm of vessel 
length was counted. 
 
 
3.9.3 Tumor Size (Surface Area and Volume)  
 
Images of the animal’s cranial window were acquired using a 1.3x objective and 
GFP fluorescence filter set of the animal’s cranial window at a set exposure of 100ms. A 
threshold was then applied that was 150 intensity units above the average background. 
The area was calculated from the pixels within the threshold limit and in the tumor area. 
This technique was used for in vivo measurements through the cranial window and also 
for the ex vivo measurements of tumor dimensions used to estimate volume using 
ellipsoidal tumor volume formula (Equation 3-1). 
 
 
3.9.4 Permeability Kinetics Measurement  
 
Rats were injected with Texas-Red dextran 3 kDa (1% solution, 0.4ml/kg).  
Images were acquired using a 1.3x objective and a Texas-Red filter set at an exposure of 
100ms. Images were acquired at 5, 10, 15, and 20 minutes post dye injection. ROI were 
drawn in tissue regions of interest (normal, peritumoral, and tumor tissue) and the 
average intensity recorded. The average intensities were normalized to their 5 minute 
value to account for differences in dye injection, light intensity, and vascular density.  
 
 
3.10 Tissue Extraction  
 
Animals were anesthetized, and 0.1ml of heparin (1000 USP units/ml, H3393, 
Sigma) was injected intracardially. Animals were then perfused with saline through the 
left ventricle of the heart after the inferior vena cava was severed. Once the blood ran 
clear and liver had turned from red to yellow/pink, the brain was extracted and coronally 
sectioned through the tumor/implantation site. Brain halves were then either snap frozen 
in OTC using liquid nitrogen and stored at -80ºC or placed in formalin and paraffin 
embedded.  
 
 
3.11 Immunofluorescence Staining 
 
Frozen brains were sectioned (10µm) using a cryostat and mounted on poly-1-
lyisne-coated glass slide. Slides will be fixed in 95% alcohol for 2.5minutes and then 
washed in distilled water. Slides were then washed 3x for 5minutes in phosphate buffered 
solution.   
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3.11.1 VEGF Immunofluorescence Staining 
 
After preparation, slides were incubated with 10% normal goat serum (sc-2043) 
for 40minutes and then incubated with mouse anti-rat VEGF antibody (sc-7269, Santa 
Cruz Biotechnology, CA) (1:50 dilution ) for one hour. Finally slides were incubated 
with Texas-Red-labeled goat anti-mouse IgG (sc-2980, Santa Cruz Biotechnology, CA) 
(1:400) for 45 minutes. Slides were then imaged with Leica microscopescope. 
 
 
3.11.2 Glial Fibrillary Acidic Protein (GFAP) Staining 
 
Paraffin embedded tissue was sectioned at 4µm and mounted on a poly-1-lyisne-
coated glass slide. Slides were stained with rabbit anti-human glial fibrillary acidic 
protein (GFAP, cat # Z0334) and rabbit immunoglobulins (negative control, cat # X0903) 
purchased from DAKO (Carpinteria, CA). The secondary antibody for GFAP, 
biotinylated goat anti-rabbit, was purchased from Vector (cat # BA-1000, Burlingame, 
CA) and used at a 1:200 dilution. Immunohistochemistry assays were performed on the 
DAKO autostainer at room temperature. Light microscopic images were captured using a 
Nikon E800 Scope. The number of GFAP-stained astrocytes was counted in five fields at 
200x magnification in the cerebral cortex overlying the hippocampus. Reactive 
astrocytes, identifiable by their star-like shape, were then manually counted and averaged 
per animal on days 15 and 66 post implant (Figure 3-3). 
 
 
3.12 Statistics 
 
Statistical analyses were conducted using SigmaStat software (SPSS Science, 
Chicago, IL). The change due to treatments , tumor, RT, Tumor + RT, Tumor + RT + 
peritumoral, compared to sham implant was determined by analysis of variance (ANOVA 
and Dunnett’s test), and a multiple comparison procedure (Tukey’s test) was used to 
discriminate among the means between groups.  Data are presented as mean±SEM, and 
differences between the means were considered to be statistically significant at a 
probability of P<0.05. 
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*
* 
Tumor implant + RT Tumor implant  
 
 
Figure 3-3. GFAP staining of rat brain tissue in a tumor implant brain 15 days post 
surgery and in a tumor implant brain following RT at 66 days. 
 
The astrogliosis staining is represented by enhanced brown color. *Denotes the tumor 
area at 15 days, and yellow arrow points to former tumor area at 66 days. 
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CHAPTER 4.  RESULTS  
 
 
Radiation initiates an inflammatory signaling cascade that is linked to early and 
late radiation sequela. Understanding the initiating events, especially those involving 
damage to the microvasculature is an important first step in any study designed to 
mitigate early and late effects of this treatment. While most normal tissue damage studies 
are carried out in irradiated normal animals, we propose a novel approach by using an 
animal brain glioma tumor model to ensure the attribution of tumor effects and improve 
the clinical relevance of our research. Tumorigenesis and progression is a complicated 
process that subverts normal homeostasis imposing new conditions favorable to tumor 
cell growth. In tumors, angiogenic processes, including those mediated through the 
secretion of VEGF, are initiated to expand the microvascular infrastructure or “network” 
and to provide support to the rapidly proliferating and very often densely cellular tumor. 
Part of the subversion process has been shown to involve the creation of an inflammatory 
milieu through the secretion of inflammatory molecules. This changing milieu is known 
to be active at the periphery of the tumor creating an angiogenic/inflammatory 
microenvironment which damages the microvasculature. The end result is a permeable 
BBB which deprives the brain of its protective barrier. The studies designed in the 
current work are unique in their use of a realistic rodent radiation toxicity model that 
includes the combined effects of tumor presence and irradiation on non-tumor (normal) 
microvasculature and tissue. This unique model has allowed us to study the long term 
effects of fractionated radiation and brain tumor presence on the tissue.  
 
 
4.1 Model Characterization 
 
We used a set of measurements to characterize our C6 glioma in situ rat tumor 
model. First, we used animal survival which is an indicator of the growth of the tumor. In 
addition, the weights of the animals were monitored every 5 days which can also be an 
indicator of tumor growth due to the drop in weight that occurs following the onset of 
tumor symptoms. Secondly, we used intravital microscopy to measure the surface area of 
the tumor to follow the progression of the tumor and correlate the surface area of the 
tumor with the ex-vivo size of the tumor following sacrifice. Thirdly we have performed 
staining for GFAP to indicate the degree of astrogliosis in the brain.   
 
 
4.1.1 Animal Survival  
 
Animal survival, an indicator of tumor growth, was measured over 30 days 
following surgery. The criterion for euthanasia of animals was set at loss of more than 
10% of body weight. In the tumor only group, animals either died or satisfied the 
euthanasia criterion starting at 15 days post tumor implant. 78% of animals were 
euthanized by day 25 and 22% of the rats lived to 30 days (n=18), (Figure 4-1).  
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Figure 4-1. Percent survival of rats with brain tumor implants that received no 
treatment.  
 
By 30 days, post tumor implant, only 22% of rats that did not receive any treatment were 
alive. This graph represents data collected from n=18 rats.  
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4.1.2 Animal Weight 
 
Animal weight was measured to indicate when the burden of the tumor became 
symptomatic in the animal. There was difference in the rate of the percent weight change 
between the two groups. At day 20, the sham implant group percent change in weight 
was significantly different when compared within the group versus the tumor implant 
group which was not significantly different until day 25 (P<0.05) (Figure 4-2).  
 
 
4.1.3 Tumor Surface Area 
 
Tumor surface area was measured through the cranial window every 5 days post 
implant. In the tumor implant group there was two distinct groups of animals: one group 
which succumbed to the tumor burden and another in which the tumor regressed over 
time. Even though there were two distinct patterns of growth there was no significant 
difference at 10,15,or 20 days post implant (P=0.85, P=0.54, P=0.34 respectively), 
between the two groups (Figure 4-3). The rate of tumor growth between day 5 to 15 was 
also compared between the two groups, and there was no significant difference (P=0.54) 
between the two growth rates (Figure A-3).  
 
 
4.1.4 Correlation between Tumor Surface Area, Cross Sectional Area, and Tumor 
Volume 
 
Tumor surface area was measured on the surface of the brain and correlated with 
the cross sectional surface area of the tumor, which revealed a R2 of 0.38 (P=0.055) 
(Figure 4-4A). Using the major and minor axis lengths of the tumor, measured from the 
cross section, tumor volume was estimated using the formula for a ellipsoid volume and 
correlated with the tumor surface area which produced an R2 of 0.548 (P<0.05) which is 
indicative of a medium correlations (Figure 4-4B).  
 
 
4.1.5 Astrogliosis in the Tumor Model  
 
Astrogliosis, indicative of inflamed astrocytes, was quantified from tissue cross 
sections of the brains with intact tumors and compared to sham tissue. However, since 
glioma is an astrocytic neoplasm which demonstrates several gross pathological features 
that are in common with astrogliosis, studying astrogliosis requires special care in 
choosing the studied region (Figure 3-3). Three distinct regions were chosen for our 
studies: first non-tumor cortex region contralateral to the tumor, second a primary-
peritumoral region 200µm from the edge of the tumor (defined by dense cellular mass) 
and a secondary-peritumoral region 500µm from the edge of the tumor. Two peritumoral 
regions were chosen to account for the uncertainty in delineating the edge of the tumor, 
given the astrocytic nature of the tumor cells. The number of inflamed astrocytes, defined 
by staining with GFAP, was counted in all three regions at 15 days post implant. A 
significant difference in the number of inflamed astrocytes was found in the non-tumor  
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Figure 4-2. Percent changes in animal weight over time in sham and tumor implant 
animals.  
 
The percent weight change in the tumor-implant group is higher than that observed in the 
sham-implant group at 30 days. However, note that this weight increase might be skewed 
by the fact that it is a mean of the weights of the few animals (22%, survived) that 
survived to 30 days. (n=19 for sham implant P<0.05, n=12 for tumor implant at day 0 
P<0.05, mean±SEM is shown) Arrows indicate when percent weight change became 
significantly different compared to day 0 (Dunnett’s test).  
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Figure 4-3. The difference in normalized tumor surface area within the tumor 
implant group.  
 
Within the tumor-only group there are two patterns of growths either the tumor 
continually grows until the animal has to be sacrificed due to side effects (78% of 
animals) or after 15 days the tumor begins to decline in size and the animal does not 
present tumor induced symptoms (22% of animals). Note that there is no significant 
difference between either group from 5 to 20 days. Images of the surface of the tumors 
were acquired through the cranial window using our intravital microscope every 5 days 
post surgery. A threshold was applied to the images relative to the background intensity. 
The cells have been transfected with GFP therefore they are fluorescent, and surface area 
of the tumor was calculated. (n=13 (terminal), n=4 (regressed), mean±SEM is shown). 
 
 
 
 
 
 
30 
 
 
 
y = 0.540x - 2.177
R² = 0.384
0
5
10
15
20
25
30
0 10 20 30 40 5
(A) 
0on
 th
e 
su
rf
ac
e 
of
 th
e 
br
ai
n
Surface area (mm2) of tumor cross-section
Su
rf
ac
e 
ar
ea
 (m
m
2 )
 o
f t
um
or
 
 
 
y = 0.117x + 0.283
R² = 0.548
0
5
10
15
20
25
30
0 50 100 150 200Su
rf
ac
e 
ar
ea
 (m
m
2 )
 o
f t
um
or
 
on
 th
e 
 su
rf
ac
e 
of
 th
e 
br
ai
n
Tumor volume (mm3)
 
(B) 
 
 
Figure 4-4. Correlations between in vivo tumor surface area acquired using 
intravital imaging, and (A) cross sectional surface area acquired histologically, and 
(B) estimated tumor volume from histological samples.  
 
We measured a medium correlation between our in vivo imaging and tumor area and 
volume estimated histologically. This lends support to our model and to the use of 
intravital surface area measurements to follow tumor progression and effect of treatment. 
(n=10, P=0.055 (A) and P<0.05 (B)). 
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tissue contralateral to the tumor (33.13±0.71 astrocytes/ROI, P<0.05), and at 500µm from 
the tumor edge there were (32.08±0.85 astrocytes/ROI, P<0.05) when compared to sham 
tissue (28.5±0.79 astrocytes/ROI )(Figure 4-5). 
 
 
4.2 Early Effects of Tumor Presence and Radiotherapy  
 
We used numerous methods to study the combined effect of tumor presence and 
radiotherapy on the brain. We once again measured animal survival and weight to 
establish the health of the animal. In addition, in vivo measurements of BBB 
permeability, leukocyte-endothelial interactions, and tumor surface area using intravital 
microscopy were performed. Also tissue from brains underwent immunohistochemisty 
staining for VEGF protein and GFAP.   
 
 
4.2.1 Animal Survival Post RT 
 
Without any treatment, 78% of tumor implant animals succumbed to the tumor 
burden by 25 days post surgery. Following cranial irradiation (8Gy/day from day 5 to 9, 
for a total of 40Gy) there was a drastic change in animal survival: 100% of animals which 
received RT survived to 30 days (Figure 4-6).   
 
 
4.2.2 Weight Change within the Four Experimental Groups 
 
Weights of the animals were measured every 5 days post surgery in the 4 
experimental groups: Sham implant, Tumor implant, Sham implant + RT, and Tumor 
implant + RT. At 30 days only the Sham implant + RT group (20.88±1.3 % change in 
weight) had significantly lower weight then the Sham implant groups(31.81±3.1 % 
change in weight, P<0.05). The weight in the Tumor implant group (49.03±1.45 % 
change in weight) was higher than all other experimental groups, but it is only 
significantly higher than the Sham implant + RT group (P<0.001) (This may be due to 
the limited number of animals at that time point) (see Figure 4-7). To determine at which 
time point within each group it became significantly different than day 5 Dunnett’s test 
was run. For all groups, except for tumor implant, they became significantly different on 
day 20 and Tumor implant became significant on day 25 (P<0.05) (Figure 4-7). 
 
 
4.2.3 Change in Tumor Surface Area Post RT  
 
Following treatment with RT (8Gy/day from day 5 to 9, for a total of 40Gy), there 
was a significant change in tumor surface area at 10, 15, and 20 days in the Tumor 
implant + RT group (3.81±0.34, P<0.05, 2.37±0.69, P<0.001, 1.40±0.85, P<0.05 
respectively) compared to the Tumor implant group (6.46±0.79, 11.63±0.89, 11.26±2.76 
respectively). (n=7 for Tumor implant + RT, n=14 day 15 and n=9 day 20 for Tumor  
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Figure 4-5. The number of activated astrocytes. 
 
Astrogliosis found in three different regions of interest: contralateral to the tumor, at 
200µm and 500μm from the tumor. There was a significant increase in the number of 
activated astrocytes contralateral to the tumor and at a distance of 500μm from the tumor 
(n=3, *P<0.05 compared to sham implant using Dunnett’s test, mean±SEM are shown). 
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Figure 4-6. Percent survival of rats with brain tumor-implants with and without 
radiation treatment.  
 
By 30 days post tumor implant, only 22% of the rats which did not receive any treatment 
were alive. Rats that received RT had a 100% survival at the 30 days time mark. These 
animals also survived to 65 days (data not shown). Total number of animals in these 
studies were; n=18 for the tumor-implant only group and n=8 for the Tumor implant + 
RT group. 
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Figure 4-7. Percent weight change measured in the four experimental animal 
groups; sham implant, tumor implant, sham implant + RT, and tumor implant + 
RT.  
 
The percent weight change in the tumor-implant group is higher than that observed in the 
sham-implant group at 30 days. However, note that this is weight increase might be 
skewed by the fact that it is a mean of the weights of the few animals (22%) that survived 
to 30 days. Arrows indicate when percent weight change became significantly different 
compared to day 0 within the group (Dunnett’s Test). For Sham implant, Sham implant 
+RT, and Tumor implant + RT it was at 20 days, and Tumor implant followed day 25. At 
30 days only the Sham implant + RT group (20.88±1.3% change in weight) was 
significantly different than all other groups (*P<0.05 vs. all other groups) (n=19 sham 
implant, n=12 tumor implant, n=15 Sham implant + RT, and n=26 Tumor implant + RT 
at day 0, mean±SEM is shown). 
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implant group. On day 30 following implant there was no detectable tumor presence on 
the surface of the brain in the Tumor + RT group (Figure 4-8).   
 
 
4.2.4 BBB Permeability Changes in the Peritumoral Region  
 
Following the administration of RT (8gy/day from day 5 to 9, total of 40Gy), 
there was no significant increase in BBB permeability at 11 days post surgery compared 
to the sham implanted animals. However, at 16 days post-surgery there was significant 
change in permeability in all groups when compared to Sham implant (27.46±1.17 x10-7 
cm/s; Peritumoral 31.75±0.85 x10-7 cm/s, P<0.05), Sham implant + RT (34.97±1.02 x10-7 
cm/s P<0.001, and Peritumoral + RT 36.74±1.88 x10-7 cm/s, P<0.001) (Figure 4-9).   
 
 
4.2.5 Adhered Leukocytes in the Brain Vasculature Following Tumor Implant and RT 
 
Adhered leukocytes were counted in the brain vasculature at 10 and 15 days 
following surgery. Measurements were limited to venules with diameters between 45-
90μm. Number of adhered leukocytes per 100μm of vessel length was found to be 
significantly higher in the Peritumoral + RT group (1.27±0.46 adhered leukocytes, 
P<0.05) vasculature at 10 days compared to Sham implant (0.53±0.21 adhered 
leukocytes). At 15days post surgery there was no significant change in the number of 
adhered leukocytes compared to the Sham implant group (Figure 4-10A).  
 
 
4.2.6 Rolling Leukocytes in the Brain Vasculature Following Tumor Implant and RT 
 
Rolling leukocytes were counted at the same time as adhered leukocytes in the 
same vasculature. Following RT at 10 days post surgery, there was a significant increase 
in rolling leukocytes in the Sham implant + RT group (8.00±0.93, P<0.001) compared to 
the Sham implant group 2.73±0.54. In addition, at 10 days the RT-only group had a 
significantly higher number of rolling leukocytes than the peritumoral group (3.17±0.55, 
P<0.001). At 15 days post surgery the same pattern was observed. The Sham implant + 
RT group (7.76±0.41) was higher than the Sham implant group (2.23±0.18 P<0.001) and 
peritumoral group (1.46±0.46, P<0.001). The Sham implant + RT group also had 
significantly higher rolling leukocyte than the Peritumoral + RT group (P<0.05). The 
Peritumoral + RT group also had significantly higher number of rolling leukocytes at 15 
days than the Peritumoral group (P<0.01) (Figure 4-10B).  
 
 
4.2.7 Astrogliosis Following Tumor Implantation and Radiation 
 
Following tumor implantation and RT (38.05±1.45 # of astrocytes/ROI), the 
degree of astrogliosis was significantly higher than all other groups: Sham implant 
(28.53±0.79, P<0.001), Tumor implant contralateral to the tumor (33.13±0.72, P<0.05),  
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Figure 4-8. Normalized tumor surface area measured using intravital imaging. 
 
Normalized tumor surface area as seen through the cranial window at 5 day intervals post 
surgery in Tumor implant and Tumor implant + RT groups. By 30 days the tumor had 
regressed in the Tumor implant + RT group and was not visible on the surface of the 
brain (*P<0.05, **P<0.001, compared to tumor implant student t-test ) (n=17 Tumor 
implant, n=7 Tumor implant + RT, mean±SEM are shown).  
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Figure 4-9. Changes in BBB permeability following tumor implant and 
radiotherapy.  
 
We measured a significant increase in BBB permeability at 16 days post surgery for the 
Tumor-implant, Sham implant + RT, and in the Tumor implant + RT groups compared to 
Sham implant group. The combination of tumor presence and RT resulted in higher BBB 
permeability than tumor presence or RT alone (n≥5 for all groups, **P<0.001, *P<0.05 
Dunnett’s test compared to sham implant, mean±SEM is shown). 
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Figure 4-10. The effect of tumor growth and radiation on leukocyte-endothelial cell 
interactions in non-tumor vessels. 
 
(A) Number of adhered leukocytes per 100μm of vessel length was significantly higher in 
the Peritumoral + RT vasculature at 10 days compared to sham implant. (B) Number of 
rolling leukocytes per 100μm of vessel length at 10 and 15 days. Sham implant + RT and 
Peritumoral + RT was significantly higher  than sham-implant (*P<0.05 vs. sham-
implant, **P<0.001 compared to sham implant, #P <0.05 and ##P<0.001 compared to 
Tumor implant, Tukey’s Test, mean±SEM is shown).  
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and Tumor implant at a distance of 500μm away from the tumor (32.08±0.85, P<0.05) 
(Figures 4-11, 4-12 and 3-3). 
 
 
4.2.8 VEGF Immunoflourescence Staining 
 
Brains were extracted at 10 and 15 days following tumor implant in animals with 
and without RT and coronally sectioned at the tumor location. Tissue sections were then 
stained for VEGF and images acquired in three different regions: tumor middle, 
peritumoral, and contralateral to the tumor location (refer to Figure 4-13). At 10 and 15 
days following tumor implant, there is more VEGF located in the peritumoral region then 
the normal tissue. In addition the tumor middle also is expressing VEGF. After RT, 
intensity of VEGF increased in the peritumoral and tumor tissue at 10 days. Due to the 
decrease in tumor size following RT, it was difficult to locate the tumor at 15 days 
following RT therefore no images of the peritumoral tissue could be taken (Figure 4-13). 
 
 
4.3 Late Effects of Tumor Presence and Radiotherapy   
 
One of the long term objectives of our work is to test the hypothesis that RT-
induces an acute response that results in a chronic inflammatory microenvironment 
leading to the amplification of radiation sequela. Having established a novel brain tumor-
radiation model to study side effects of radiotherapy and used this model, in the previous 
section, to characterize the acute effects of radiation, we proceed to studying the long-
term effect of radiation. In this section we will present the results of our studies on the 
long-term effect of radiation on BBB permeability, leukocyte adhesion, and astrogliosis 
using intravital imaging and histological analysis. 
 
 
4.3.1 Radiation-Induced Late Effects on BBB Permeability 
 
Intravital microscopy was performed at 66 days following surgery in tumor 
implanted animals which had undergone RT and sham implanted animals. At 66 days 
post RT, there was still significant difference in BBB permeability in the Peritumoral + 
RT (34.88±0.39 x10-7 cm/s) compared to sham (30.79±0.83 x10-7 cm/s, P<0.05) (Figure 
4-14). 
 
 
4.3.2 Radiation-Induced Late Effects on Leukocyte Adhesion 
 
Leukocyte adhesion was measured in the same vascular bed as the BBB 
permeability measurement at 65 days post surgery in tumor implanted animals which had 
undergone RT and sham implanted animals. Unlike the BBB permeability the degree of 
leukocyte adhesion was not significantly different between the peritumoral + RT group 
and sham implant group (P=0.38) (Figure 4-15A). 
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Figure 4-11. The number of reactive astrocytes following tumor implant and RT.  
 
Following tumor implantation and RT, the degree of astrogliosis was significantly higher 
than all other groups; Sham implant, Tumor implant contralateral to the tumor, and 
Tumor implant at a distance of 500μm away from the tumor (n=3,**P<0.001 compared 
to sham, # P<0.05 compared to Tumor implant (contralateral), $P<0.05 compared to 
Peritumoral, Tuckey’s test, mean±SEM are shown).  
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Figure 4-12. Images of GFAP stained rat brain tissue in sham implant, tumor 
implant + RT, and tumor implanted animals.  
 
There is an increase in the number of reactive astrocytes in the tumor implant with and 
without RT. Note the intensity of staining in the middle of the tumor due to the C6 cells 
being an astrocytic neoplasm (the star shaped brown colored cells are the reactive 
astrocytes) (n=3). 
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Figure 4-13. Immuflourescence staining of VEGF at 10 and 15 days in tumor 
implant and tumor implant + RT animals.  
 
Images of coronally sectioned brain tissue at 10 and 15 days post implant with and 
without RT (400x magnification VEGF= red, C6-GFP cells=green, cell nuclei=blue).  
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Figure 4-13 (continued). 
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Figure 4-14. Change in BBB permeability at 66 days following RT. 
  
Significantly higher permeability was found in the Peritumoral + RT group compared to 
the sham implant group (n=3 sham implant, n=4 peritumoral + RT, *P<0.05, T-test, 
mean±SEM is shown).  
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Figure 4-15. Quantification of the leukocyte-endothelial interactions at 65 days post-
surgery. 
 
There was no significant difference in the number of (A) adhered and (B) rolling 
leukocytes between the Sham implant and Peritumoral + RT groups (n=3 sham implant, 
n=4 peritumoral + RT, mean±SEM is shown).   
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4.3.3 Radiation-Induced Late Effects on Leukocyte Rolling  
 
Leukocyte rolling was quantified at 65 days post surgery in tumor implanted 
animals which had undergone RT and sham implanted animals. Similar to leukocyte 
adhesion the degree of leukocyte rolling was not significantly different between the 
peritumoral + RT group and sham implant group (P=0.62) (Figure 4-15B). 
 
 
4.3.4 Radiation-Induced Late Effects on Astrocytes  
 
Reactive astrocytes were stained in brain tissue from sham implant and post tumor 
implant + RT animals at 66 days post surgery. Sections were then imaged and the number 
of reactive astrocyte quantified. At 66 days post RT in tumor implant animals (29.0±2.28 
astrocytes/ROI) there was a significant increase in the number of reactive astrocytes 
(astrogliosis) compared to sham implanted animals (20.8±2.28 astrocytes/ROI, P<0.05), 
(Figure 4-16). 
 
 
4.4 The Use of Thalidomide to Minimize RT-Induced Damage 
 
One of the main goals of our research had been to find potential therapeutics that 
could be used to minimize the effects of RT-induced damage to the normal tissue. The 
model we have created is ideal to test potential therapeutics because it has the ability to 
observe the effect of the treatment and ensures that it does not reduce the efficacy of RT 
on the tumor. In this section we will present the results of our studies on the early and 
long-term effect of thalidomide treatment given concomitantly with RT in our brain 
tumor model on BBB permeability, leukocyte adhesion, and astrogliosis using intravital 
imaging and histological analysis 
 
 
4.4.1 Animal Survival  
 
Animal survival, an indicator of tumor growth, was measured over 30 days 
following surgery. Unlike the tumor implanted group, the Tumor implant + RT + 
Thalidomide, 100% of animals lived to 30 days and were followed to 65 days post  
surgery without incident similar to the that of the Tumor implant + RT group (Figure 4-
17). To see survival depicted as animal numbers see Figure A-1. 
 
 
4.4.2 Percent Change in Weight over Time 
 
The weight change in animals was monitored post surgery every 5 days to 
monitor for symptoms of tumor burden. The animals gained weight to day 5 and then lost 
to day 10 due to effects of anesthesia and repeated RT. The thalidomide treated animals 
(10.01±1.23% change in weight) lost more weight than the Sham implant group 
(2.95±1.9% change in weight, P<0.001) and Tumor implant + RT group (-1.80±1.28 
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Figure 4-16. The late effect of RT and tumor presence on astrogliosis. 
 
At 66 days following surgery in tumor implanted rats which had undergone RT there was 
a significant increase in the number of reactive astrocytes compared to sham implant 
animals (n=3, *P<0.05, mean±SEM is shown). 
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Figure 4-17. Percent survival of rats with brain tumors with and without treatment.  
 
By 30 days only 22% of rats were alive who did not receive any treatment. Rats who 
received RT with and without thalidomide treatment had a 100% survival to 30 days 
which was followed to 65 days (data not shown) without any deaths.  
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change in weight, P<0.001) which may credited to the lethargy thalidomide induces and 
combined effect of anesthesia. After day 10 animals proceeded to gain weight up to day 
65 post surgery (Figure 4-18). 
 
 
4.4.3 Comparison of the Growth Kinetics between Experimental Groups 
 
Radiation significantly altered the growth pattern of C6 tumors in rats at 15 and  
20 post-implant compared to the tumor implant group leading to regression of the tumor 
in all animals which underwent treatment(P<0.001, and P<0.05 respectively). However, 
when the combination of RT and thalidomide were used concomitantly it significantly 
altered the growth of the C6 tumors causing it to closely mimic the growth pattern of the 
Tumor-only group. In addition the RT + Thalidomide (7.24±1.25 normalized tumor 
surface area) group had significantly different tumor growth at 15 days compared to RT 
only (2.37±0.69 normalized tumor surface area, P<0.05) (Figure 4-19). Even with a 
significant change the growth kinetics the tumors in the RT + Thalidomide group also 
regressed over 30 days. 
 
 
4.4.4 Ex Vivo Tumor Volume Estimation 
 
After animal sacrifice brains, were excised and sectioned into half at the tumor 
site. Intravital microscopy was then used to measure the axis of the tumor which was then 
applied to a formula to calculate ellipsoid tumor volume. Unlike the surface area 
measurement, no significant difference could be determined among the groups (Figure 4-
20). In appendix A the corresponding graph of cross sectional area is available (Figure A-
4).  
 
 
4.4.5 Tumor Growth in Immunocompromised Mice Following Treatment 
 
Following treatment, both RT-only and RT + Thalidomide tumors were measured 
every 3 days following treatment and compared to control tumors. At 3 and 6 days 
following treatment the RT-only group (0.87±0.12 and 0.15±0.15) had significantly 
different tumor size compared to control (1.48±0.15 and 2.72±0.27, P<0.05) (comparison  
at 9 days not possible because control animals were sacrificed due to tumor size). At 6 
days the RT + Thalidomide group (1.65±0.14 normalized tumor volume) was also 
significantly different from the control values (P<0.05). In addition at 9 days following 
treatment the RT + Thalidomide group (2.46±0.24) had a significantly higher normalized 
tumor volume than the RT-only group (1.46±0.23, P<0.05) (Figure 4-21). 
 
 4.4.6 In Vitro Testing of Thalidomide Treatment 
 
To investigate further the ability of thalidomide to protect during RT we 
performed an in vitro experiment in which C6 cells were irradiated with 8Gy with and  
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Figure 4-18. Percent weight change over time in three experimental groups; sham 
implant, tumor implant + RT, tumor implant + RT + thalidomide.  
 
The weight change in animals was monitored post surgery every 5 days. The animals 
gained weight to day 5 and then lost to day 10 due to effects of anesthesia.  Note the large 
decrease in animal weight in the animal treated with thalidomide (P<0.05) which may be 
due to the lethargy thalidomide induces and combined effect of anesthesia. After day 10 
animals proceeded to gain weight up to day 65 post surgery (n=19 Sham implant, n=26 
Tumor implant + RT at day 0, n=14 Tumor implant + RT + Thalidomide, arrows indicate 
when P<0.05 within the group, Dunnett’s test, mean±SEM is shown). 
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Figure 4-19. The difference in normalized tumor surface area between treatment 
groups using our cranial window technique.  
 
Graph showing the difference in tumor surface area between the groups; Tumor implant, 
Tumor implant + RT (40 Gy total) and Tumor implant + RT (40Gy total) + Thalidomide 
(100mg/kg). Images of the surface of the tumors were acquired through the cranial 
window using our intravital microscope every 5 days post surgery. A threshold was 
applied to the images relative to the background intensity, the cells have been transfected 
with GFP therefore they are fluorescent, and surface area of the tumor was calculated. 
(n=17 Tumor implant, n=7 Tumor implant + RT, n=7 Tumor implant + RT+ 
Thalidomide, *P<0.05 compared to Tumor-only, **P<0.001 compared to Tumor implant, 
#P<0.05 compared to Tumor + RT +Thalidomide, Tuckey’s test, mean±SEM is shown).  
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Figure 4-20. Ex vivo estimated tumor volume in tumor implant, tumor implant + 
RT, and tumor implant + RT + thalidomide animals. 
 
After animal sacrifice brains were excised and the tumor sectioned and imaged. The axis 
of the tumor were measured and applied to a formula to calculate ellipsoid tumor volume. 
No significant difference was found between the groups; Tumor implant, Tumor implant 
+ RT, and Tumor implant + RT + Thalidomide. (n≥3 for all groups, Dunnett’s test, 
mean±SEM is shown).  
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Figure 4-21. Normalized tumor growth of flank tumors in immunocompromised 
mice following treatment.  
 
Mice had C6 cell injected into the right flank. When the tumor reached ≈550mm3, 
treatment was started as either RT-only or RT + Thalidomide. Tumors were measured 
using calipers every 3 days post start of treatment. The group of animals treated with 
thalidomide had significantly larger tumor volume at day 9 post treatment (P<0.05). (n=5 
Control, n=11 RT only + RT, n=4 RT + Thalidomide, *P<0.05 compared to Control, 
#P<0.05 compared RT only, Tuckey’s test, mean±SEM is shown). 
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without thalidomide treatment (1ug/ml, 10ug/ml and 100ug/ml of media). To establish if 
thalidomide protect the cells from RT damage we measured the number of dead cells 
using a trypan blue assay and also counted the number of cells at each time point. No 
protective effects were identified because all samples irradiated with thalidomide 
treatment were significantly different from control cells but not from RT-only cells 
(Figure 4-22). 
 
 
4.4.7 BBB Permeability Following Treatment with Thalidomide 
 
Using intravital microscopy, BBB permeability was measured in 5 experimental 
groups over time: Sham implant, Peritumoral, Sham implant + RT, Peritumoral + RT, 
Peritumoral + RT + Thalidomide.  At 11 days none of the groups was significantly 
different P=0.466. By day 16 Sham implant + RT (34.97±1.03 x10-7 cm/s, P<0.001), 
Peritumoral + RT (x10-7 cm/s 35.59±1.5, P<0.001) and Peritumoral + RT + Thalidomide 
(33.53±1.3, P<0.05) were significantly different from the sham implant (27.46±1.17 x10-7 
cm/s). In addition at 66 days Peritumoral + RT (34.88±0.39 x10-7 cm/s, P<0.05) and 
Peritumoral + RT + Thalidomide (36.037±0.79 x10-7 cm/s, P<0.05) were still 
significantly different the sham implant (Figure 4-23).  
 
 
4.4.8 New Method of Measuring Permeability in Tissue 
 
The current method of measuring permeability restricts us to a small area of 
vascular bed due to the requirement of needing a high magnification to visualize the 
tissue. As a side project, we have tried measuring permeability at a low magnification 
over the period of 20 minutes to see if we would be able to detect change in the 
permeability of the tissue. We performed this measurement in tumor tissue or the 
equivalent because technically the tumor tissue should be the most permeable, so we 
would expect the best chance of seeing a change. To measure changes in permeability in 
the tumor region (or the equivalent in sham groups), we injected Texas-Red dye and 
measured the intensity of the tissue at 5, 10, 15 and 20 minutes. We normalized the 
intensities over 5 minutes to account for difference in the amount of dye, and vascularity 
of the tissue. At 20 minutes there was a significant difference in intensity between the 
Tumor tissue (1.016±0.02) compared to Sham tissue (0.85±0.01, P<0.001), Peritumoral + 
RT (0.88±0.04, P<0.05) and Sham implant + RT (0.89±0.02, P<0.05) (Figure 4-24).  
 
 
4.4.9 Changes in Leukocyte Adhesion Following Treatment 
 
Leukocyte adhesion was measured at 10, 15 and 65 days post surgery. Changes in 
leukocyte endothelial adhesion were only evident at 10 and 65 days post surgery. The 
only group at 10 days that showed a significant increase above Sham implant 
(0.529±0.21 adhered leukocytes /100μm of vessel length) was the Peritumoral + RT 
group (1.268±0.16, P<0.05). At 65 days post implant there was a significant difference 
between Sham implant (0.38±0.18 adhered leukocytes /100μm of vessel length) and the  
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Figure 4-22. A C6 rat glioma in vitro cell experiment. 
 
To investigate further the ability of thalidomide to protect during RT, we performed an in 
vitro experiment in which C6 cells were irradiated with 8Gy with and without 
thalidomide treatment. (A) Trypan blue assay was used to measure the percent of dead 
cells and the total (B) number of cells were also counted at the corresponding time points. 
No protective effects were identified (n=3, &P<0.05 significantly different from all other 
groups, Tuckey’s test, mean±SEM is shown).   
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Figure 4-23. Combined graph of the early and late changes in BBB permeability.  
 
At 11 days none of the groups was significantly different P=0.466. By day 16 Sham 
implant + RT (34.97±1.03 x10 -7 cm/s, P<0.001), Peritumoral + RT (x10 -7 cm/s 
35.59±1.5, P<0.001) and Peritumoral + RT + Thalidomide ( 33.53±1.3, P<0.05) were 
significantly different from sham implant ( 27.46±1.17 x10 -7 cm/s). In addition at 66 
days Peritumoral + RT (34.88±0.39 x10 -7 cm/s, P<0.05) and Peritumoral + RT + 
Thalidomide (36.037±0.0.79 x10 -7 cm/s, P<0.05) were still significantly different the 
sham implant (n= 5 Periutmoral + RT + Thalidomide*P<0.05, *P<0.001 compared to 
sham implant, Dunnett’s test, mean±SEM is shown).   
 
 
 
 
 
 
57 
 
 
 
 
 
 
0.8
0.85
0.9
0.95
1
1.05
1.1
5 10 15 20
Av
er
ag
e 
in
te
ns
ity
 in
 ti
ss
ue
 R
O
I (
no
rm
al
iz
ed
 to
 
5 
m
in
.)
Post dye injection (minutes)
Sham implant
Sham implant + RT
Tumor implant
Tumor implant + RT
Tumor implant  + RT + Thalidomide
 
 
$ 
% 
** 
 
 
Figure 4-24. Novel method of measuring permeability in tumor tissue. 
 
To measure changes in permeability in the tumor region (or the equivalent in sham 
groups), we injected Texas-Red dye and measured the intensity of the tissue at 5, 10, 15 
and 20 minutes. We normalized the intensities over 5 minutes to account for difference in 
the amount of dye, and vascularity of the tissue. At 20 minutes there was a significant 
difference in intensity between the Tumor tissue compared to Sham tissue, Peritumoral + 
RT and Sham implant + RT (n≥5 per group, **P<0.001 compared to sham, %P<0.05 
compared to Sham implant + RT, $P<0.05 compared to Tumor implant + RT, Tuckey’s 
test, mean±SEM). 
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Peritumoral + RT group (0.738±0.16, P<0.05). In addition, within the Peritumoral + RT 
group there was a significant decline in adhered leukocytes between time points 10 and 
15 days and 10 vs 65 days post surgery (P<0.05, Dunnett’s test (Figure 4-25A).  
 
 
4.4.10 Changes in Leukocyte Rolling Following Treatment  
 
Changes in leukocyte rolling along the vasculature wall were evident at 10 and 15 
days post surgery. At 10 and 15 days the Sham implant + RT (8.00±0.93, P<0.05 and 
7.76±0.41 rolling leukocytes/vessel, P<0.001, respectively) and Peritumoral + RT + 
Thalidomide (6.35±1.1, P<0.05 and 6.24±1.26 rolling leukocytes/vessel, P<0.05 
respectively) were both significantly higher than sham values at both time points 
 (2.74±0.54 and 2.23±0.18 rolling leukocytes/vessel respectively). Also at 10 days the 
Sham implant + RT had significantly higher numbers of rolling leukocytes then the 
Peritumoral group (3.17±0.55, P<0.05). At 15 days the groups Sham implant + RT 
(P<0.001), Peritumoral + RT + Thalidomide (P<0.001), Peritumoral + RT group 
(4.36±0.62, P<0.05) all had significantly higher leukocyte rolling numbers than the 
Peritumoral group (1.47±0.46). Also at 15 days there was a significant difference 
between the RT-only and Peritumoral + RT group enforcing that the presence of the 
tumor alters RT-induced damage in the BBB (P<0.05). In addition in the Sham implant + 
RT group, and Peritumoral group the number of rolling leukocytes went down 
significantly from day 10 to 15 within the group (P<0.05, ANOVA) . Also within the 
thalidomide treated group there was a significant decrease in leukocytes from day 10 
compared to 65 (P<0.05, ANOVA) (Figure 4-25B). 
 
 
4.4.11 Changes in Number of Reactive Astrocytes 
 
Reactive astrocytes were stained in brain tissue from Sham implant, Tumor 
implant + RT,  Tumor implant + RT + Thalidomide animals  at 66 days post surgery. 
Sections were then imaged and the number of reactive astrocyte quantified. At 66 days 
post RT in tumor implant animals (29.0±2.28 astrocytes/ROI) and in animals treated with 
thalidomide (34.3±2.03 astrocytes/ROI), there was a significant increase in the number of 
reactive astrocytes (astrogliosis) compared to sham implanted animals (20.8±2.28 
astrocytes/ROI, P<0.05) (Figures 4-26 and 3-4). 
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Figure 4-25. Early and late changes in leukocyte-endothelial interactions.   
 
(A) On day 10 the peritumoral + RT group had a significantly higher number of adhered 
leukocytes then sham implant. At 65 days post surgery, the animals treated with 
thalidomide had a significantly higher number of adhered leukocytes then sham
(B) On day 10 and 15 rolling leukocytes were significantly different between Sham 
implant+RT and Thalidomide treated animals vs. sham (n≥4 Peritumoral + RT 
 implant. 
Thalidomide, *P<0.05 compared to sham implant, %P<0.05 vs. Peritumoral, $P<0.05 
s. Peritumoral + RT, #P<0.05 vs. peritumoral, Tuckey’s test, mean±SEM is shown). 
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Figure 4-26. Number of activated astrocytes at 66 days post surgery. 
 
At 66 days following surgery in tumor implanted rats which had undergone RT, there 
as a significant increase in the number of reactive astrocytes compared to sham implant 
nimals (n=3, *P<0.05, Dunnett’s test, mean±SEM is shown). 
 
w
a
 
 
 
 
 
 
 
 
 
 
61 
CHAP
n the normal brain 
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allowed us to evaluate the efficacy of thalidomide as a potential therapeutic to minimize 
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t is an allograft model which can evoke an alloimmune response in 
Wistar rats. This immune response could mask, add or change the response of normal 
tissue t
y. As a result the BED of our 
TER 5.   DISCUSSION 
 
 
In this work, we developed and characterized a novel rat radiation brain tumor 
model that enabled us to study the effect of a brain tumor and RT o
tissue at acute and late tim
n toxicity of normal tissue using intravital microscopy and 
immunohistochemistry.  
 
Our studies show that the presence of the tumor alone caused quantifiable changes
in BBB permeability, leukocyte-endothelial interactions, astrogliosis, and caused an 
increase in VEGF protein expression in the peritumoral region. Treatment with cran
radiation further caused a measurable change in BBB permeability that was significant
higher than sham implant values at 15 days and altered the kinetics and degree of the 
leukocyte-endothelial interaction rolling, astrogliosis, and VEGF expression in the 
peritumoral region.  We also evaluated thalidomide as a 
onstrated that it had lim
immunocompromised mice in 
 
5.1 Model Characterization 
 
The broader goal of this study was to develop a clinically relevant animal brain 
radiation toxicity model. Many in vivo RT studies are performed on normal animals that 
have no tumors.84 One limitation of such studies is that they do not account for the 
abnormal microenvironment created by the tumor presence. Ignoring this presence could 
under or over estimate the true amount of damage caused by RT. In this study we used a 
cranial window brain tumor model in rats. To the best of our knowledge, our study is the 
first attempt to evaluate the combination of tumor presence and RT in a murine model on 
RT-induced damage to normal brain. To this end we employed a C6 rat glioma cell l
which has been transfected to express GFP. This fluorescence characteristic enabled us to 
measure tumor size and to delineate the edges of the tumor, making it possible to measure 
changes in the peritumoral region. This, tumor delineation ability, coupled with our 
ability to study the same rat and microvascular bed over time using our window model
a major step forward in brain radiation studies. One of the limitations of our model is 
the C6 glioma in ra
o tumor presence. However, in humans high grade tumors can also be weakly 
immunogenic.119  
 
To further strengthen the clinical relevance of our model, we decided to use a 
fractionated radiotherapy regimen. Again, the vast majority of studies use high single 
doses of irradiation up to 30Gy.120-122 In our current model we decided to fractionate our 
radiotherapy into 5 doses of 8Gy for a total dose of 40G
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treatment is 1.25x that a patient would receive (80Gy regimen fractionated RT). This is in 
contras ly, 
 
ld 
f 
 
 
 al. 
 
ile providing them 
structural proteins and growth factors. While this process may ensure the survival of the 
cells in
, in 
hanged 
 a 
-
tion 
 VEGF.  Dirkx et al. showed that when tumor-
bearing mice were treated with an anti-VEGF antibody, the number of leukocyte-
ays 
nd 
t to single doses of 20 or 30Gy which are 1.375 and 3 times higher, respective
then the patient equivalent BED at 80Gy (Table C-1).   
 
To characterize our tumor model in Wistar rats we measured animal weight, 
survival, tumor growth, BBB permeability, leukocyte-endothelial interactions, and VEGF
expression. We found that with no treatment to hinder the growth of the tumor, rats 
fulfilled the criteria set for euthanasia starting from 16 days post-tumor implant due to 
symptoms induced by tumor burden thus limiting the time frame during which we cou
perform our experiments. The most common symptom of tumor burden was sudden 
ataxia  which  affected the drinking and eating routines of these animals resulting in a 
decrease in their body weight. In a small percentage of rats, 22%, the tumor began to 
regress after 15 days of growth resulting in an increase in these animal’s survival time 
(were followed out to 30 days). The 22% survival rate we observed is higher than that 
reported by Parsa et al. which found that 11% of Wistar rats following implantation o
106 C6 cells survived to 30 days.123 Parsa, et al. have shown that by day 15 post tumor 
implantation, anti-glioma antibody titers (a measurement of humoral immune response to
the tumor) could be detected which coincides with the time point at which a limited
number of tumors began to regress. There are some differences between our experimental 
designs that might explain the discrepancy in our survival times. First, while Parsa et
implanted the tumor cells anterior to the bregma we implanted posterior to it. This 
difference in anatomical location could affect the tumor growth rate. Second, Parsa, et al.
injected  the tumor cells using saline while we injected in Matrigel. Matrigel, which 
solidifies at body temperature, physically encapsulates the cells wh
 a foreign environment, it may also hinder their spread, contrary to the cells in 
saline, confining them to one location and delaying their growth.  
 
To investigate the effect of tumor presence on the peritumoral tissue, we 
quantified the number of leukocyte-endothelial interactions, a marker of inflammation
the venules. We found that the number of adhered or rolling leukocytes were unc
from sham levels in the peritumoral region at 10 and 15 days. Others have observed
reduction in leukocyte-endothelial interactions caused by tumor presence which they 
speculated to be part of the tumor’s mechanism for evasion of the host immune 
response.124 Studies have shown that one possible mechanism by which leukocyte
endothelial interactions are reduced in the tumor is driven in part by the down-regula
of adhesion molecules induced by 125-127
endothelial interactions in the tumor vessels increased, although interactions in non-
tumor vessels did not change.128  
 
 There was a significant increase in peritumoral BBB permeability at 15 d
following tumor implant. This phenomenon is seen in the clinic: brain tumors usually 
cause excessive edema which leads to increased interstitial pressure in the brain which 
can hinder the delivery of therapeutics to the tumor. Structurally, in tumors, the 
vasculature is denser, chaotic, tortuous and immature lacking a basement membrane a
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have decreased pericyte coverage causing it to be leaky and dilated.10,13,14 According
studies have shown that at certain growth stages tumors are very permeable. Tum
presence, with few exceptions, results in BBB damage.129,130 Furthermore, the tumor 
induced angiogenic signaling causes an increase in VEGF and its receptor which is 
known to initiate a signaling cascade that leads to, among other things, vascular 
permeability. Angiogenic signaling can also cause the formation of vesiculo-vacuol
organelles (VVOs), which are multiple vesicles fused together, endothelial fenestration,
and opening of the cell junctions which leads to the deposition of proteins in the 
interstitium that facilitates angiogenesis.131 Feng et al.29,132 have shown that VVOs 
regulated transendothelial cell passage when exposed to permeability-inducing factor
including inflammation, and that regulation of permeability through VVOs has been 
shown to increase in tumor microvessels. The occurrence of increased BBB p
ly, 
or 
ar 
 
s, 
ermeability 
 the peritumoral region may be explained by an increase of VVOs associated with 
 
 in the 
 
gliosis was detectable in the contralateral hemisphere. No 
significant difference in reactive astrocyte numbers could be measured at 200μm from the 
tum r but it may be due to the excessive staining in this area making it hard to quantify 
 
 
ease 
as 
nnect 
 
 of 
 
in
VEGF expression, especially considering that a higher level of VEGF protein was found
in the peritumoral region compared to both tumor center and normal tissue.  
 
 There was also a significant increase in the number of reactive astrocytes
peritumoral region (500μm from the tumor) and contralateral to the tumor compared to 
sham implanted animals. The extent (distance) of the tumor influence is quite interesting
considering that astro
o
the exact numbers.  
5.2  Tumor and Radiation-Induced Early Changes  
 
In our study, we irradiated rats with brain tumors to find the effect of the 
combined presence of radiation and tumor on the normal tissue. Localized brain 
irradiation was delivered to tumor implanted rats starting from day 5 and for five days 
until day 9 following tumor implant using a fractionated regimen of 8Gy/day for a total 
of 40Gy. Radiation treatment hindered tumor growth significantly, from day 10 to 20 
compared to the tumor-implant group, and led to tumor regression in all animals. On day 
10, following tumor implant (1 day following end of RT), there was a significant incr
in adhesion of leukocytes compared to the sham-implant animal group. By day 15 the 
adhered leukocyte counts had returned to sham levels. In addition, BBB permeability w
significantly higher in the tumor-implant + RT group compared to the sham-implant 
group at 15 days but not 10 days. This result is interesting because there is a disco
between increase in BBB permeability and changes in adhered leukocytes. Yuan et al.
have shown that when rats underwent irradiation with a localized brain single dose
20Gy, changes in BBB permeability mimicked changes in leukocyte-endothelial 
interactions.83 Wilson et al. observed a strong correlation between BBB permeability 
changes and leukocyte adhesion; also using a single dose of 20Gy localized brain 
irradiation.91 There are several possible reasons that might explain the decorrelation 
between permeability and leukocyte activity changes in our model. The first reason may
be due to the change in RT regimen. Fractionation of radiation consists of lower doses 
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per daily treatment which means the delivery of a lesser insult at any given session and 
more time for the tissue to heal between doses. These factors together alter the kinetics 
and magnitude of the inflammatory modulators responsible for upregulation of leukocyte-
endothelial interactions. In a different study and using a different fractionation regimen 
(2Gy/day for 20 days with weekends off; for a total of 40Gy), Yuan et al. showed 
following fractionated RT, changes in BBB permeability were delayed while changes i
leukocyte endothelial interactions were undetectable.84 The second possible reason, for 
the decorrelation, is that the tumor presence may be responsible for the change in 
permeability through the upregulation of cytokines such as VEGF without necessarily 
affecting leukocyte-interactions. Therefore the change in permeability would not depend
on changes in leukocyte-endothelial interactions. It is important to note that following 
radiation we did find an increase in VEGF expression in the tumor and peritumoral t
at 10 days. The third possible reason could be the ability of the tumor to down regulate 
leukocyte-endothelial interactions resulting in the decrease in leukocyte interactions at 
day 15 post- implant, especially considering that none of the leukocyte-endothelial 
interactions in the tumor-implant group (without radiation treatment) were significant at 
any time point compared to the sham-implant group. Wu et al. showed that when tumor 
bearing tissue was irradiated, the number of leukocytes rolling and adhering to the 
microvessels either did not change in the peritumoral and tumor vasculature or decreased 
in number.127,133 Even though we had some change in leukocyte-endothelial interactions,
this study demonstrates that the tumor has the ability to alter the kinetics and magnitu
of interactions and the difference between the two studies, type of tumor, tumor locatio
and RT dose could explain contradictions between these two studies. In addition, Wu et
al. found that when inflammation was induced (using TNF or lipopolysaccharide) in 
tumor tissue, the normal vessels responded with an increase in adhesion and rolling of 
leukocytes whereas the tumor vessels did not.127 Further experiments investigating the 
causes responsible for pe
that 
n 
 
issue 
 
de 
n, 
 
rmeability increase following RT in our rat radiation brain tumor 
model are needed, especially considering that in the clinic 40% of glioma patients have 
increas cy 
he 
 because activated astrocytes have been shown to 
secrete inflammatory agents  which, in turn, could amplify EC and microvascular 
amage and have detrimental effects on oligodendrocytes and O-2A progenitor cells thus 
 
 
 
ed permeability a month after RT making it difficult to follow treatment effica
and tumor progression.6 
 
Following RT, the degree of astrogliosis, a marker of inflammation, went up 
significantly in the tumor bearing brains. This result helps solidify our hypothesis that t
combined effect of brain tumor presence and RT would intensify the degree of RT–
induced normal tissue. This is important
105,106
d
leading to further damage in the brain.  
5.3 Tumor Radiation-Induced Late Changes 
 
One of the most noteworthy findings of our study is the tumor limiting effect of
this RT regimen which enabled us to study RT-induced longterm damage in a rat 
radiation tumor model. We found that at 65 days post-tumor implant that BBB 
permeability was still significantly higher in the peritumoral + RT group compared to 
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sham-implant, however leukocyte-endothelial interactions returned to normal which 
correlates with studies performed by Yuan et al.84 It is interesting to note that som
irradiated rats were afflicted with malocclusion at the later time points. The exact reason
leading to the malocclusion is not known but similar results were found in a study by 
Nagler who studied the “Extended-term effects of head and neck irradiation in a 
rodent”.134 Nagler found that starting at 6 months post RT, in doses ranging from 2.5 to 
15Gy, rats began to have problems with overeruption of unground anterior incisor teeth 
in 5 out of 10 rats which was theorized to be due to the decrease in food intake resulting 
in overgrowth of their teeth. From our observations it seems more likely that the 
malocclusion was a result of lethargy caused by RT that d
e 
 
ecreased the amount of tooth 
grinding (thegosis) that rodents do to keep their teeth from becoming overgrown.  Brain 
tumor p igue.59 
r 
the 
ted 
at an 
tion-
icative of inflammation, it is associated with or is a 
byproduct of brain inflammation. It is also known that prolonged upregulation of 
astrocytes can create glial scar sites which has been theorized to inhibit axonal 
3 
n 
 to 
ainst 
f 
ial 
atients treated with cranial irradiation have been reported to suffer from fat
However, we did not investigate this matter any further. 
 
At 65 days post surgery we also found that there were significantly highe
numbers of activated astrocytes and astrogliosis compared to sham implant animals. 
Radiation has been reported to cause an inflammatory response in the parenchyma of 
mouse brain through the activation of astrocytes and microglial cells.84,101,135,136 
Cicciarello et al.102 reported activated astrocytes 90 days after treatment with fractiona
irradiation. Mildenberger et al.137 also observed a microglial response 6 months after 
fractionated irradiation. Furthermore, Reuss et al.138 and Willis et al.139 reported th
inhibition of astrocyte proliferation can affect the BBB integrity. Although radia
induced gliosis is not directly ind
regeneration or remylination.10
 
 
5.4 Thalidomide Treatment 
 
In 2006, the FDA approved thalidomide treatment for use in multiple myeloma. 
As a result of its success with multiple myeloma, thalidomide treatment is currently 
undergoing numerous phase II clinical trials for the use in brain tumors and other types of 
cancer. The exact mechanism of how thalidomide works is not known, but it is has been 
shown to reduce angiogenesis, alter the expression of adhesion molecules, reduce TNF 
levels, increase IL-10 and stimulates cytotoxic T cells.140 Unfortunately there is limited i
vivo data to support the ongoing clinical trials for brain tumors. Our model enabled us
test the efficacy of thalidomide as an anti-angiogenic and anti-inflammatory agent with 
potential to minimize radiation toxicity of normal tissue and to monitor its effect on the 
tumor.  Others have shown that thalidomide may exhibit the ability to protect ag
radiation toxicity, and it was recently used in a phase I clinical trial to study the effect o
thalidomide on modulating radiation-induced lung injury. Unfortunately the clinical tr
was terminated early due to dose limiting toxicity associated with thalidomide 
treatment.141,142 We showed that thalidomide at a dose of 100mg/kg/day administered 
concomitantly with RT interfered with RT’s efficacy in controlling tumor growth by 
measuring the surface of the tumor through the cranial window. There was a significant 
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difference between the tumor surface area in the Tumor + RT group and the Tumor + 
+ Thalidomide at 15 days post implant. Although RT tumor control wa
RT 
s affected, this 
change did not affect animal survival. In addition, thalidomide treatments seem to have 
no prot
 
ivo studies have shown that this is not the case.  
 addition, Daruwalla, et al. showed using mice with colorectal cancer that thalidomide 
treatme it 
 in vivo 
izing effect of thalidomide usually is not seen using in vitro cultures. Moreira 
t al. specifically showed that endothelial cell proliferation was inhibited by thalidomide 
ut not in glioma cells which lends support to why our in vitro study had no significant 
sults.148 
 
ective effects following RT when we measured BBB permeability, leukocyte-
endothelial interactions, and astrogliosis at early and late time points.  
 
Ansiaux et al. showed that thalidomide treatment actually radiosensitized the 
tumors to radiation treatment by increasing the amount of oxygen in the tumor.143
Differences in tumor type, thalidomide dose, RT dose and regimen may account for the 
contradictory results between our study and the Ansiaux’s study. It is hypothesized that 
thalidomide treatment alone should decrease the growth of tumor due to its anti-
angiogenic effect, but numerous in v 143-146
In
nt had no early effects on the tumor until it reached its late phase of growth, but 
did not improve animal survival.147 
 
Our in vitro results did not demonstrate any protective, radiosensitizing, and/or 
anti-angiogenic effects on irradiated rat C6 glioma cells. It is speculated that in an
setting the main effect of thalidomide is on the tumor vasculature through its anti-
angiogenic effect causing a normalization of the vasculature and hence delivering more 
oxygen to the tumor bed. This agrees with observations that have shown that the 
radiosensit
e
b
re
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CHAPTER 6.  FUTURE DIRECTIONS 
 
n 
peutics. We focused our studies on 
the peritumoral region in the brain to investigate the combined effect of tumor presence 
) The development of a rat radiation brain tumor model combined with the cranial 
) The combination of radiation and tumor presence, Tumor-implant + RT group, 
) Following our fractionated radiation regimen, the tumor underwent regression and 
(4) Treatment with thalidomide, a potential anti-angiogenic and anti-inflammatory 
drug, concomitantly with RT had no protective effects on radiation-induced 
 
um 
l as 
 
al 
t to the radiation oncology field. While executing our 
research plan, we identified several limitation of our original plan and some possible 
directio
 
 
 
6.1 Summary 
 
One of the aims of this work was to develop and characterize a rat radiation brai
tumor model that could be used to test potential thera
and radiation on the vasculature and tissue in that region. The major achievements and 
conclusions from this study can be summarized as:  
 
(1
window technique allowed progressive measurements of the tumor and 
surrounding area over time.  
 
(2
altered BBB permeability and leukocyte-endothelial interactions compared to the 
Sham-implant + RT or Tumor-implant groups. 
 
(3
the animal’s survival was 100% at 65 days allowing us to study long term 
radiation-induced damage.  
 
damage.  
 
6.2 Future Directions 
 
Side effects of radiation therapy are the main limiting factor in treatment planning 
and have great implications for patient prognosis. Understanding the mechanisms 
underlying their initiation, development and propagation would allow for the use of 
preemptive treatments that reduce or ameliorate these side effects allowing the maxim
biologically effective RT dose to be reached. This is especially important in the case of 
brain tumors were the side effects of RT include blood-brain barrier disruption, as wel
neurological, and cognitive impairment. While most RT-induced damage studies are
carried out in irradiated normal animals, we developed a novel approach using an anim
brain glioma model which ensures the incorporation of tumor effects and renders our 
model more clinically relevan
ns that could be explored in future research. In what follows, we will identify 
these possible future studies: 
 
Radiation toxicity studies have been focused on normal tissue damage with the
aim of understanding the mechanisms underlying such damage. This approach has an
68 
obvious limitation, in that if one’s aim is to maximize the effect of radiation treatment 
then the effect of radiation on tumor tissue is also a part of this endeavor. Our model 
allows for such studies of radiation effects on the tumor as well as normal tissue. A 
logical 
mor 
 
e 
? One 
lay in the regression of the tumor. Another possible experiment would 
be to study the hematopoietic response to tumor presence alone and combined with RT, 
by anal
ast 
lial 
d 
o use 
our 
r astrocyte expression. However, there are 
numerous other drugs which work through other mechanisms such as NF-κB pathway 
that cou  
ed 
al 
0, 120 and 180 days need to be characterized. This model would 
also allow for studies in the same animal that correlate vascular changes such as BBB 
ermeability and leukocyte interactions with functional and behavioral changes that occur 
t later time points.  
 
 
extension of our work would then be to study radiation effects on tumor tissue 
using our model.  
 
In our model RT, limited the growth of the tumor which then led to full tu
regression in all animals. One possible area of study would be to investigate what leads to
this regression. Is the regression a result of RT slowing tumor growth and allowing th
immune system to develop an effective response to tumor presence or is the RT 
sensitizing the immune system to the tumor by upregulation of adhesion molecules
straightforward study that could address this issue would be to implant the tumor in 
immunocompromised rats and see if the same phenomenon of RT leading to tumor 
regression would still occur. This experiment would explain what role the RT and 
immune system p
yzing the peripheral blood to determine whether the immune system is activated 
and its kinetics. 
 
Another avenue of research is to continue searching for potential anti-angiogenic 
and/or anti-inflammatory agents that would not interfere with RT tumor efficacy. In p
research from our group, we confirmed that BBB permeability and leukocyte endothe
interactions could be abrogated by treating with antibodies of ICAM and TNF before an
after localized cranial irradiation in normal animals.83,91 In this study, we tried t
thalidomide, which has been shown to down regulate TNF expression. Although 
findings are not conclusive and are limited to only one tumor cell line, thalidomide did 
not exhibit any significant reduction of radiation toxicity as measured by BBB 
permeability, leukocyte interactions o
ld possibly limit radiation toxicity while not interfering with RT tumor efficacy.
Our model is ideal for such studies.  
 
A focus of our research has been to link the early changes in BBB permeability 
after RT with late changes that are more clinically relevant. The animal model we creat
will enable us to study the possible link between early and late damage in a more clinic
relevant model due to the presence of the tumor. Further research of this model at later 
time points, such as 9
p
a
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APPENDIX A. SUPPLEMENTAL DATA 
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Figure A-1. Graph depiction of the number of surviving animals at each five day 
time point.  
 
Animals which did not undergo RT had drastically reduced survival times compared to 
those who received RT. Thalidomide treatment did not affect the survival to 65 days post 
surgery (not shown).  
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Figure A-2. Correlation between tumor volume estimated from the tumor area on 
the surface of the brain and coronal cross sectional area. 
 
Volume was estimated using the axis measurements of the tumor on surface of the brain 
and the cross sectional measurements. There is a correlation factor of R2 = 0.376 
(P=0.059, n=10). 
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Figure A-3. Plots of the rate of growth from 5 to 15 days in the tumor implant 
group.  
 
To try and distinguish between the terminal tumor implant group (top graph) and the 
tumor implant group that regressed (bottom graph) the slopes of their growth were 
graphed. No significant difference could be found between the two groups (n=14). 
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Figure A-4. Cross sectional area of the tumor post sacrifice. 
 
The cross sectional area of the tumor was measured post sacrifice to investigate if there 
was a significant difference between the groups.  No significance was found (mean±SEM 
are shown, Dunnett’s test). 
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Figure A-5. Correlation between change in permeability and leukocyte interactions.  
 
No significant correlation could be found between permeability and leukocyte 
interactions.  
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APPENDIX B. DIFFERENCE BETWEEN PERMEABILITY DYES 
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Figure B-1. Images of the brain vasculature post dye injection of Texas-Red and 
FITC dextran. 
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Figure B-1 (continued). 
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Table B-1. Comparisons of average intensities. 
 
 Average Intensity   Average Intensity  
 Vessel Tissue Difference  Vessel Tissue Difference 
Pre 166 162 6 Pre 192 287 -95* 
0.5 1487 829 658 0.5 1054 742 312 
5 776 482 294 5 438 427 11 
10 607 398 209 10 313 349 -36* 
15 534 364 170 15 286 345 -59* 
20 459 328 131 20 284 346 -62* 
40 373 283 90 40 209 292 -83* 
 
FITC would be the permeability tracer of choice because the hemoglobin blocks its 
fluorescence therefore it limits the amount of fluorescence in the tissue from vasculature 
fluorescence scatter. * Negative number indicates that the tissue is brighter in intensity 
than the vessel. 
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APPENDIX C. BIOLOGICAL EFFECT DOSE (BED) CALCULATIONS 
 
 
BED formula: 
BED= D x (1 + d/ (α/β))                       (Equation C-1) 
 
α/β = 2 (for the brain)  
d = dose per fraction 
D = total dose 
BED = biological effect dose 
 
 
Single dose: 
High Single Dose of 20 Gy: 
20(1+(20/2)) = 220 BED 
 
High Single Dose of 30 Gy: 
30(1+(30/2)) = 480 BED 
 
 
Fractionated regimen: 
Fractionated Regimen of 40 Gy Total: 
40(1+(8/2)) = 200 BED 
Reverse calculation to find the equivalent dose (Gy) 
200/(1+(2/2)) = 100 Gy 
 
 
Clinical regimen: 
60Gy in Patients: 
60(1+(2/2)) = 120 BED 
 
80Gy in Patients: 
80(1+2/2)) =160 
 
 
Table C-1. Comparisons of the different radiation regimens. 
 
Radiation Regimen Dose (Gy) Fraction (Gy) BED 
Single Dose 20 N/A 220 30 N/A 480 
    
Fractionated Dose 40 8 200 
    
Patient Dose 60 2 120 80 2 160 
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